Zwangerschapsafbreking in het tweede trimester

Initiatief: NVOG Aantal modules: 5

Methode zwangerschapsafbreking in het tweede trimester

Publicatiedatum: 20-11-2026
Beoordeeld op geldigheid: 20-11-2026

Uitgangsvraag

Welke methode heeft bij tweede trimester zwangerschapsafbreking de voorkeur: instrumenteel of medicamenteus?

Aanbeveling

Bespreek in geval van een zwangerschapsafbreking in het tweede trimester met de cliënt de beschikbare behandelopties (instrumenteel en medicamenteus), de (potentiële) voor- en nadelen en de individuele voorkeuren van de cliënt.

 

Beslis daarna samen welke methode wordt toegepast.

Overwegingen

Voor- en nadelen van de interventie en de kwaliteit van het bewijs

In de literatuuranalyse is onderzocht of er verschil is in uitkomsten tussen instrumentele en medicamenteuze zwangerschapsafbreking in het tweede trimester. Het was niet mogelijk op basis van de beschikbare literatuur om onderscheid te maken tussen vroege en late tweede trimester zwangerschapsafbreking. Er werd één systematische review (Schmidt-Hansen, 2020) met twee geschikte RCT’s en één losse RCT gevonden. Daarnaast werden negen observationele studies meegenomen in de literatuuranalyse voor uitkomstmaten waarvoor geen bewijs werd gevonden uit de RCT’s. De bewijskracht voor de cruciale uitkomstmaten ‘ernstige maternale morbiditeit’ en ‘late effecten op fertiliteit en zwangerschap’ werd beoordeeld als zeer laag vanwege methodologische beperkingen, conflicterende resultaten en imprecisie. Voor de belangrijke uitkomstmaten ‘maternale sterfte’, ‘cliënt ervaringen’ en ‘mentale gezondheid’ werd ook een zeer lage bewijskracht gevonden vanwege dezelfde redenen. Het is dan ook lastig om conclusies te verbinden aan de gerapporteerde resultaten.

 

De observationele studies hebben allen als beperking dat er een relatief kleine studiepopulatie is met een relatief korte follow-up en daarmee zijn lange termijn complicaties nauwelijks onderzocht. De bewijskracht voor al deze uitkomstmaten is zeer onzeker (GRADE zeer laag).

Er is één observationele studie (Little, 2015) met vroeggeboorte als uitkomstmaat. In deze retrospectieve cohort studie (n=173) wordt weliswaar significant minder vroeggeboorte gezien na eerdere instrumentele zwangerschapsafbreking in vergelijking met medicamenteuze zwangerschapsafbreking, maar de bewijskracht hiervoor is zeer laag. Cliënten in deze studie kregen een zwangerschapsafbreking op verschillende indicaties waaronder ook IUVD en pPROM. Zeker die laatste indicatie zorgt voor bias omdat cliënten met pPROM onafhankelijk van methode van afbreking al een verhoogd risico hebben op vroeggeboorte in een volgende zwangerschap. Daarnaast werd het merendeel van de cases geëxcludeerd vanwege incomplete data waardoor er mogelijk een grote selectiebias is.Het merendeel van de observationele studies rapporteerde korte termijn complicaties zoals bloedverlies, infectie en heropname. Er werd geen verschil gevonden in korte termijn complicaties tussen beide groepen.

Eén observationele studie (Kelly, 2010) met 122 cliënten vond een hogere cliënt-tevredenheid na instrumentele zwangerschapsafbreking in vergelijking met medicamenteuze zwangerschapsafbreking (100% vs 53%). Grimes 2004 met 18 deelnemers vond geen verschil en Bourgine 2005 vond bij 29 cliënten ten tijde van de 1 jaars follow-up geen verschil in depressie en rouwverwerking. De observationele studies brengen door hun beperkte data en methodologische tekortkomingen weinig extra bewijskracht (GRADE zeer laag).  

 

Op basis van bovenstaande literatuuranalyse is er geen uitspraak te doen over een verschil in complicatierisico op korte en lange termijn tussen instrumentele zwangerschapsafbreking en medicamenteuze zwangerschapsafbreking in het tweede trimester.

 

Er zijn in de literatuur echter wel indirecte aanwijzingen dat instrumentele behandeling in het tweede trimester geassocieerd is met een verhoogde kans op vroeggeboorte in een eventuele volgende zwangerschap.

 

Saccone (2016) beschrijft in een grote systematische review en meta-analyse de relatie tussen een instrumentele verwijdering van een zwangerschap en obstetrische uitkomsten in een volgende zwangerschap. Hierin werden alleen studies geïncludeerd waarbij vrouwen een instrumentele zwangerschapsafbreking of behandeling voor een miskraam ondergingen. De controlegroep bestond uit vrouwen die geen instrumentele behandeling  hadden ondergaan. Er zijn geen studies in deze review waarin vrouwen met een instrumentele afbreking in het tweede trimester direct werden vergeleken met vrouwen met een medicamenteuze tweede trimester zwangerschapsafbreking

 

In totaal rapporteerden 27 studies over vroeggeboorte in een volgende zwangerschap na instrumentele zwangerschapsafbreking. Vijf van deze studies in Saccone (2016) rapporteerden specifiek over vroeggeboorte na D&E (Daling, 1977; Meirik, 1984; Foix-Helias, 2001; McCarthy, 2013; Woolner, 2014). De termijn werd niet expliciet gespecificeerd in deze studies maar aangenomen wordt dat de methode in geval van “dilatation and evacuation” (D&E) tweede trimester zwangerschapsafbrekingen betreft. Daarnaast rapporteerden twee studies over vroeggeboorte in de volgende zwangerschap na medicamenteuze zwangerschapsafbreking waarbij de controlegroep eveneens bestond uit vrouwen zonder medicamenteuze afbreking (Winer, 2009; Mirmilstein, 2009). Vrouwen die een tweede trimester instrumentele afbreking hadden ondergaan, hadden een hoger risico op vroeggeboorte in een volgende zwangerschap dan vrouwen zonder zwangerschapsafbreking (OR 1.39 CI 1.08-1.80). Vrouwen die een medicamenteuze afbreking hadden ondergaan hadden net geen significant verhoogd risico op vroeggeboorte in een volgende zwangerschap vergeleken met vrouwen zonder zwangerschapsafbreking (OR 1.50 CI 1.00-2.25).

Er is wel beschikbare literatuur over de lange termijn uitkomsten na eerste trimester miskraam of zwangerschapsafbreking. Een systematische review en meta-analyse van Lemmers (2016) laat zien dat bij cliënten met een eerste trimester miskraam of zwangerschapsafbreking, instrumentele behandeling. zowel vaccuümaspiratie als dilatatie en curettage) geassocieerd is met een hogere kans op vroeggeboorte in een volgende zwangerschap vergeleken met cliënten die een medicamenteuze behandeling in de voorgeschiedenis hadden (OR 1.19 CI 1.10-1.28).

 

Hooker (2014) concludeert in een systematische review en meta-analyse dat curettage in het eerste trimester een risicofactor is voor intra-uterine adhesies. Intra uteriene adhesies kunnen asymptomatische zijn en niet ontdekt, maar kunnen resulteren in cyclusstoornissen en invloed hebben op fertiliteit. De klinische relevantie van intra-uteriene adhesies op lange termijn reproductieve uitkomsten (kans op conceptie, kans op zwangerschap en miskraam percentage) wordt door gebrek aan studies niet beschreven in deze review.

 

Door het ontbreken van studies die een directe vergelijking maken tussen instrumentele en medicamenteuze zwangerschapsafbreking in het tweede trimester van de zwangerschap is er sprake van een kennislacune.

Het staat niet onomstotelijk vast dat de uitkomsten van medicamenteuze en instrumentele zwangerschapsafbrekingen in het eerste trimester zondermeer kunnen worden geëxtrapoleerd naar het tweede trimester. Er zijn verschillende hypotheses over het ontstaan van vroeggeboorte na een instrumentele zwagerschapsafbreking.

Het is bijvoorbeeld onduidelijk wat het effect is van cervicale dilatatie en van cervicale priming voorafgaand aan de procedure op de uitkomsten. De theorie dat meer dilatatie  in het tweede trimester leidt tot meer schade en daardoor een hogere kans op vroeggeboorte, zou pleiten voor een voorkeur voor medicamenteuze behandelopties. Echter een andere hypothese is dat met name door gebruik van (scherpe) curettage, zoals gebruikelijk is in het eerste trimester maar niet in het tweede trimester, de basale laag in het endometrium wordt beschadigd wat kan leiden tot intra uterine adhesies of placenta adherentie problematiek in een volgende zwangerschap.

Het risico op intra-uteriene adhesies is mogelijk verhoogd na het gebruik van scherpe curettage techniek in vergelijking to vacuumcurettage en bij herhaaldelijke chirurgische behandelingen. Daarnaast is er literatuur beschikbaar dat er minder intrauteriene adhesies gezien worden na echogeleide handmatige vacuum aspiratie versus electrische vacuum aspiratie bij miskramen.  (Westendorp, 1998; Dempsey 2008; Chung 2024) Theoretisch zou er dan voor tweede trimester behandelingen met mechanische evacuatie een minder grotere de kans op intra-uteriene adhesies kunnen bestaan, dit is echter niet aangetoond.

 

Hoewel de bewijskracht voor een verhoogd risico op vroeggeboorte na instrumentele zwangerschapsafbreking in het tweede trimester dus laag is, is er geen literatuur beschikbaar die het tegendeel laat zien. Een medicamenteuze behandeling zou daarom wellicht te prevaleren zijn, met name voor vrouwen met een reproductieve toekomst. De werkgroep is van mening dat de verschillende behandelopties met de vrouw besproken dienen te worden, met de potentiële voor- en nadelen, waarna gezamenlijk een keuze voor een methode gemaakt kan worden.

In de huidige infrastructuur van abortuszorg in Nederland onderstreept de werkgroep het belang en noodzaak van intensievere samenwerking tussen gynaecologen en abortusartsen. Het over en weer verwijzen tussen abortusartsen en gynaecologen is geen op dit moment geen gebruikelijke praktijk. Abortusartsen ervaren een drempel om cliënten naar het ziekenhuis te verwijzen voor een medicamenteuze zwangerschapsafbreking. Dit kan de counseling beinvloeden. Het ontbreken van mogelijkheden tot medicamenteuze afbreking binnen de abortusklinieken, moet geen reden zijn om clienten informatie over potentiele risico’s te onthouden. Locale regionale afspraken voor doorverwijzing zijn van groot belang om de onderlinge samenwerking te optimaliseren met als doel optimale zorg rondom zwangerschapsafbreking (module Randvoorwaarden rondom zwangerschapsafbreking).

 

Waarden en voorkeuren van patiënten (en evt. hun verzorgers)

In de beschikbare literatuur is het onduidelijk of er een verschil is in korte termijn complicaties tussen instrumentele en medicamenteuze zwangerschapsafbreking in het tweede trimester van de zwangerschap. Er is nauwelijks bewijs beschikbaar over lange termijn uitkomsten op toekomstige zwangerschappen na instrumentele of medicamenteuze zwangerschapsafbreking in het tweede trimester. Er zijn echter wel indirecte aanwijzingen dat een instrumentele zwangerschapsafbreking mogelijk geassocieerd zou kunnen zijn met een verhoogde kans op vroeggeboorte in een eventuele volgende zwangerschap. De kans op eventuele nadelige effecten op vruchtbaarheid of toekomstige zwangerschap zou met name doorslaggevend kunnen zijn in de keuze van cliënten met een toekomstige kinderwens.  

 Enkele studies beschrijven het sociaal emotioneel welbevinden en/of tevredenheid van de procedure die de cliënt heeft ondergaan waarbij cliënten na een instrumentele behandeling mogelijk iets tevredener zijn dan na een medicamenteuze zwangerschapsafbreking. De bewijskracht is zeer laag door verschillende soorten bias. Er is dus geen uitspraak te doen of er een verschil in sociaal emotioneel welbevinden en/of tevredenheid over de verschillende procedures.

Een overweging in de keuze voor de methode van zwangerschapsafbreking kan zijn dat er wensen zijn rondom het afscheid (begraven of cremeren) van de foetus en eventueel indicatie of verzoek voor aanvullende diagnostiek (zie module Opties van aanvullend onderzoek op materiaal (foetus-placenta)).

 

Kosten (middelenbeslag)

Er kan geen betrouwbare uitspraak worden gedaan over de kosten-effectiviteit van verschillende behandelingen. Er zijn geen kosten-effectiviteitsanalyses verricht die kosten voor instrumentele en medicamenteuze zwangerschapsafbreking met elkaar hebben vergeleken. Dit is een kennislacune. Wanneer medicamenteuze afbreking een kleiner risico geeft op vroeggeboorte in vergelijking met instrumentele afbreking dan zal dit al heel snel kosten effectiever zijn dan instrumentele afbreking aangezien de kosten van een neonatale behandeling en opname na vroeggeboorte hoog zijn.

 

Aanvaardbaarheid, haalbaarheid en implementatie

De huidige infrastructuur voor abortuszorg in Nederland in het tweede trimester is nu zo ingericht dat cliënten waarbij foetale afwijkingen of een relevante maternale aandoening geen rol spelen zich voor de zwangerschapsafbreking wenden tot een abortuskliniek. Omdat een abortuskliniek geen 24-uurs zorg kan leveren krijgen deze cliënten daar een instrumentele zwangerschapsafbreking. Is er echter sprake van foetale afwijkingen of ernstige maternale ziekte, dan wordt de zwangerschapsafbreking doorgaans uitgevoerd in een ziekenhuis, waar expertise met betrekking tot instrumentele zwangerschapsafbreking in het tweede trimester veelal niet aanwezig is. Cliënten krijgen dan in principe een medicamenteuze behandeling. Dit aspect wordt verder besproken in module Nazorg.

 

Logistieke implicaties (Jaarrapportage Wafz, IGJ, oktober 2023)

Uit de jaarrapportage van de Wet afbreking zwangerschap (Wafz) bleek dat in 2022 in Nederland 35.606 vrouwen een zwangerschapsafbreking ondergingen; 3.020 in ziekenhuizen en 32.568 in abortusklinieken. Vijftien procentan deze afbrekingen vond plaats in het tweede trimester en 2,2% tussen 22+0 en 23+6 weken. In het tweede trimester werden in ziekenhuizen 1.150 zwangerschappen afgebroken en 3.856 in abortusklinieken (instrumenteel ). Er is niet bekend hoeveel van de vrouwen die een instrumentele tweede trimester zwangerschapsafbrking hebben ondergaan, zouden opteren voor een medicamenteuze zwangerschapsafbreking in een ziekenhuis als zij die keuzemogelijkheid beschikbaar was. In theorie zou dit kunnen neerkomen op een toename van het aantal vrouwen met een wens tot medicamenteuze zwangerschapsafbreking in het tweede trimester in het ziekenhuis. Het zou hierbij gaan om relatief kleine aantallen mits deze zorg goed gespreid wordt over alle ziekenhuizen. Het is daarom niet de verwachting dat de capaciteit van de zorg hiermee ernstig overschreden zal worden.

 

Rationale van de aanbeveling: weging van argumenten voor en tegen de interventies

Door gebrek aan direct vergelijkende studies met voldoende bewijskracht is er geen uitspraak te doen over een verschil in korte en lange termijn complicaties tussen een instrumentele of medicamenteuze bij een zwangerschapsafbreking in het tweede trimester.  Er is wel literatuur beschikbaar die zonder directe vergelijking tussen instrumentele en medicamenteuze afbreking een mogelijke associatie veronderstelt met vroeggeboorte in een volgende zwangerschap na instrumentele zwangerschapsafbreking in het tweede trimester. Vanuit studies in het eerste trimester van de zwangerschap na miskraam en zwangerschapsafbreking is wel een associatie met vroeggeboorte in een volgende zwangerschap en een verhoogde kans op adhaesies beschreven.

Op dit moment zijn in Nederland de beschikbare behandelmethodes afhankelijk van de setting (en lokale infrastructuur rondom doorverwijzen) waarin de cliënt zich presenteert. In elke setting dienen cliënten te worden voorgelicht over beide beschikbare methoden en de potentiële voor- en nadelen dienen te worden besproken, waarbij de cliëntenvoorkeur de basis moet zijn om tot een keuze te komen.

Onderbouwing

Zwangerschapsafbrekingen vinden plaats in een abortuskliniek of in een ziekenhuis, afhankelijk van indicatie, termijn en voorkeur van de cliënt. Vanaf 1 januari 2025 vinden afbrekingen tot 9 weken ook medicamenteus plaats bij de huisarts. Zwangerschappen in het tweede trimester worden in Nederlandse ziekenhuizen doorgaans medicamenteus afgebroken, dit in tegenstelling tot afbrekingen in abortusklinieken waarbij in het tweede trimester altijd instrumenteel afgebroken wordt na medicamenteuze voorbehandeling van de cervix. Er is onduidelijkheid of een tweede trimester instrumentele afbreking gepaard gaat met meer kans op lange termijn complicaties in vergelijking tot een medicamenteuze afbreking. In het buitenland is tweede trimester instrumentele afbreking gangbaarder. Sinds de invoering van de NIPT (2017) en sinds de komst van 13 weken echo (2021 Imitas studie) volgen er mogelijk meer verzoeken voor zwangerschapsafbrekingen vroeger in het tweede trimester in plaats van laat in het tweede trimester na tweede trimester SEO “20-weken echo” omdat foetale afwijkingen eerder worden gediagnosticeerd. Met oog op goede cliënteninformatie en samen beslissen is het essentieel meer inzicht te krijgen in de verschillende behandelmethoden medicamenteus versus instrumenteel; de vroege en late complicaties van zowel medicamenteuze als instrumentele tweede trimester zwangerschapsafbreking, organisatorische randvoorwaarden, en belevingsaspecten.

  1. Severe maternal morbidity

NO GRADE

No evidence was found regarding the effect of instrumental termination of pregnancy on ICU admission when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on readmission when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Autry, 2002; Kapp, 2021; Sonalkar, 2017; Turok, 2007

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on hemorrhage when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Chhetri, 2015; Kelly, 2010

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on blood transfusion when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Autry, 2002; Chhetri, 2015; Kapp, 2021; Sonalkar, 2021; Turok, 2007; Whitely, 2011

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on uterine infection when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Tufa, 2021; Turok, 2007; Whitley, 2011

 

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on sepsis when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Chhetri, 2015

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on trombovenous events when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Jacques, 2021; Whitley, 2011

 

  1. Late fertility and pregnancy effects

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on risk of premature birth in following pregnancy when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Little, 2015

 

NO GRADE

No evidence was found regarding the effect of instrumental termination of pregnancy on risk of abnormal placentation in following pregnancy, return of menstrual cycle, and fertility/Asherman when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

  1. Maternal death

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on maternal death when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Sonalkar, 2017; Whitley, 2011

 

  1. Patient experiences

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on satisfaction when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Grimes, 2004; Kelly, 2010

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on acceptability when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Grimes, 2004; Kelly, 2010

 

  1. Mental health

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on post-traumatic stress, depression, anxiety, and psychological morbidity when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Kelly, 2010

 

Very low GRADE

The evidence is very uncertain about the effect of instrumental termination of pregnancy on levels of grief when compared with medical termination of pregnancy in the second trimester of pregnancy.

 

Source: Burgoine, 2005

 

NO GRADE

No evidence was found regarding the effect of instrumental termination of pregnancy on long-term coping, adjustment, doubt, well-being, and relief when compared with medical termination of pregnancy in the second trimester of pregnancy.

Description of studies

An overview of the characteristics of the included studies is provided in table 1.

 

Autry (2002) performed a retrospective cohort study to compare complication rates of women who underwent dilation and evacuation or medical abortion between 14 and 24 weeks of gestation. In total, 139 women underwent instrumental abortion and 158 women received medical abortion because of fetal or maternal indications, preterm premature rupture of membranes or intrauterine fetal death Groups were not comparable at baseline. Women who underwent medical abortion had a higher gestational age, while the instrumental abortion group was more likely to have Laminaria placed and underwent abortion for maternal indications more frequently. Outcomes of interest were readmission and hemorrhage with blood transfusion.

 

Burgoine (2005) performed a prospective cohort study to compare grief resolution after dilatation and evacuation (D&E) or induction of labor (IOL) for second-trimester pregnancy termination. English literate women between 18 and 45 years with a diagnosis of a second-trimester fetal anomaly, and after options counseling, choosing to terminate their pregnancy were included. In total, 22 women received D&E and 27 women IOL by either vaginal misoprostol or intravenous oxytocin. Groups were comparable at baseline. Outcomes of interest were depression and grief.

 

Chhetri (2015) performed a randomized control trial to determine the effectiveness of instrumental versus medical methods for second trimester abortions in Nepal. Women undergoing a termination of intrauterine pregnancy (not because of fetal abnormalities) between 12 to 18 weeks based on the last menstrual period and on obstetric ultrasonography with a singleton pregnancy and hemoglobin of ³ 10 gm/dL were included.  Instrumental abortion consisting of cervical priming with misoprostol followed by dilatation and evacuation (D&E) was performed in 66 women and 75 women underwent medical abortion consisting of mifepristone 200 mg followed by misoprostol 400 mcg vaginally or sublingually after admission until the woman expels the fetus. A maximum of five doses were used four hours apart. Groups were comparable at baseline. Outcomes of interest were hemorrhage, blood transfusion and sepsis.

 

Grimes (2004) performed a pilot randomized controlled trial to compare mifepristone-misoprostol versus dilatation and evacuation (D&E) for mid-trimester abortion. English speaking women of at least 18 years with a fetal biparietal diameter of 26 to 46 mm (corresponding to 13.9–19.9 weeks of gestation) were included. Women that experienced a fetal death and those having a fetus with congenital anomalies or chromosomal defects were included. In total, 18 women were randomized. Nine women underwent D&E after one or two days of laminaria preparation and nine women received mifepristone-misoprostol treatment (mifepristone 200 mg orally followed in two days by misoprostol 800 mcg vaginally, and then misoprostol 400 mcg orally every 3 hours). Groups were comparable at baseline. The outcome of interest was patient experience.

 

Jacques (2021) performed a retrospective cohort study to compare complication rates of dilation and evacuation (D&E) to mifepristone and misoprostol labor induction for second trimester abortion for fetal indications. Women who had a second trimester abortion for fetal anomaly or demise between 14 weeks 0 days and 23 weeks 6 days were included. In total, 75 women underwent instrumental termination of pregnancy with D&E and 81 women received labor induction with mifepristone and misoprostol (mifepristone 200 mg orally and 800 mcg vaginally followed by 400 mcg vaginally or buccal). Groups were not comparable at baseline. The gestational age was on average 3 weeks earlier in women receiving instrumental abortion than women undergoing medical abortion. Outcomes of interest were hemorrhage and trombovenous events.

 

Kapp (2021) performed a retrospective chart review to determine whether ultrasonography prior to dilation and evacuation (D&E) or medical abortion ≥13 weeks was correlated with safety. All women undergoing an abortion at or after 13 weeks’ gestation for medical reasons with no upper gestational age limit, either by medical or surgical means, where at least some primary or secondary outcomes were recorded were included. In total, 593 women underwent instrumental abortion with D&E and 1,701 women received medical abortion using mifepristone and misoprostol. Groups were not comparable at baseline. Nineteen percent of the women undergoing D&E were nulliparous as compared to 33% of the women receiving medical abortion. Besides, 90% of the women undergoing D&E had a gestational age between 13 and 15 weeks while this was 52% for women receiving medical abortion. Outcomes of interest were readmission and hemorrhage.

 

Kelly (2010) performed a randomized controlled trial to compare psychological outcomes and acceptability of medical versus instrumental termination of pregnancy at 13 to 20 weeks of gestation. Women accepted for termination of pregnancy, with pregnancies between 13 + 0 and 19 + 6 weeks of gestation at the time of abortion were included. Women with fetal congenital abnormalities were excluded. In total, 122 women were randomized. Sixty-two women underwent instrumental termination of pregnancy with vacuum aspiration and 60 women received medical termination of pregnancy with mifepristone-misoprostol treatment (mifepristone 200 mg orally, and 36 to 48 hours later misoprostol 800 mg vaginally followed by misoprostol 400 mg vaginally or orally every 3 hours ). Groups were comparable at baseline. Outcomes of interest were hemorrhage, patient experience and mental health.

 

Little (2015) performed a retrospective chart review to assess whether second trimester pregnancy termination with dilation and evacuation (D&E) vs induction of labor (IOL) affects subsequent risk of preterm birth. Women who underwent a second trimester pregnancy termination at 17 to 24 weeks of gestation for fetal anomalies, fetal death or previable preterm rupture of membranes (PPROM) without signs of spontaneous labor, such as

cervical dilation were included. In total, 130 women underwent D&E and 43 women received IOL with either high-dose misoprostol alone or mifepristone and high-dose misoprostol. Groups were not comparable at baseline. Women with prior D&E were more likely to be white, have private insurance, and have undergone the termination for fetal anomalies or death, while they were less likely to have had a history of a preterm delivery prior to that pregnancy termination. Besides, women with prior D&E had undergone the procedure at an earlier gestational age. The outcome of interest was the risk of premature birth in following pregnancy.

 

Sonalkar (2017) performed a retrospective cohort study to determine complications associated with medical induction with misoprotostol and dilation and evacuation (D&E) for second-trimester uterine evacuation. Women who underwent uterine evacuation between 14 and 24 weeks of pregnancy were included. Indications for uterine evacuation were induced abortion, preterm premature rupture of membranes, intrauterine fetal death, maternal health, and fetal anomaly. In total, 343 women underwent D&E and 122 women received medical induction with misoprostol. Groups were not comparable at baseline. Women differed in pregnancy length, parity and indication for procedure. Outcomes of interest were readmission, blood transfusion, and maternal death.

 

Tufa (2021) performed a quasi-experimental study to assess the effectiveness and safety of dilation and evacuation as compared to medical abortion between 13 and 20 weeks of pregnancy. Women with a gestational age between 13 and 20 weeks confirmed with ultrasound with an age ³18 years willing to provide informed consent for the study and had a working phone and willingness to be contacted for a follow-up questionnaire 2 weeks after the procedure were included. In total, 60 women underwent D&E and 219 received medical abortion with mifepristone followed by misoprostol. The termination of pregnancy was elective. Groups were similar at baseline except for age, place of residence and prior delivery. Women who underwent instrumental abortion were older and more women had a prior vaginal delivery. Outcomes of interest were uterine infection and patient experience.

 

Turok (2007) performed a retrospective cohort study to determine complications and charges in women undergoing second trimester D&E at a university hospital (Hospital D&E) or a private outpatient facility (Clinic D&E) or induction of labor (Hospital Induction). Women with a termination of pregnancy between 13 and 24 weeks of gestation were included. In total, 83 women underwent Hospital D&E, 253 women underwent Clinical D&E and 89 women received Hospital Induction. Indications for termination were intrauterine fetal demise, fetal anomaly, fetal condition incompatible with life or severe maternal medical conditions. However, in the Clinic D&E group, most women underwent elective termination of pregnancy (98%). Groups were not similar at baseline. Women who underwent Clinic D&E were younger, had fewer ceasarean section deliveries and fewer medical problems than the two other groups. In addition, the gestational age was higher for women in the Hospital Induction group. Outcomes of interest were readmission, blood transfusion, and uterine infection.

 

Whitley (2011) performed a retrospective cohort study to assess the optimal procedure for midtrimester uterine evacuation. All women undergoing a planned midtrimester uterine evacuation procedure between 13+0 to 23+6 weeks were included. In total, 94 women underwent D&E and 126 women received medical abortion with prostaglandins. Indications for termination were chromosomal or genetic abnormalities, structural abnormalities, fetal demise, maternal medical condition or preterm premature rupture of membranes. Groups were not comparable at baseline. Women who underwent D&E were older, more likely to be white and to have private insurance and less likely to be Hispanic. Besides, they had an earlier median gestational age at the time of the procedure, were more likely to have undergone invasive diagnostic testing, and were more likely to have had cervical ripening prior to the procedure. Outcomes of interest were blood transfusion, uterine infection, trombovenous events, and maternal death.

 

Table 1. Characteristics of included studies

Author (year)

Study design

Timing of pregnancy termination

Indication

Intervention (n)

Control (n)

Outcome measures

Autry (2002)

Observational study

14 to 24 weeks

Fetal or maternal indications, preterm premature rupture of membranes or intrauterine fetal death

D&E

n=139

Medical abortion (specifically misoprostol)

n=158

Readmission and blood transfusion

Burgoine (2005)

Observational study

Second trimester

Fetal abnormalities

D&E

n=22

Misoprostol or intravenous oxytocin

n=27

Depression and grief

Chhetri (2015)

RCT

12 to 18 weeks

No fetal abnormalities

Priming with misoprostol, followed by D&E

n=66

Mifepristone followed by misoprostol

n=75

Hemorrhage, blood transfusion, and sepsis

Grimes (2004)

RCT

13.9 to 19.9 weeks

Fetal death, congenital anomalies or chromosomal defects

Laminaria preparation followed by D&E

n=9

Mifepristone followed by misoprostol

n=9

Patient experience

Jacques (2021)

Observational study

14+0 to 23+6 weeks

Fetal anomaly or demise

D&E

n=75

Mifepristone followed by misoprostol

n=81

Hemorrhage and thrombovenous events

Kapp (2021)

Observational study

>13 weeks

Medical reasons (intrauterine demise, fetal anomaly, severe oligohydramnios, inevitable spontaneous abortion)

D&E

n=593

Mifepristone followed by misoprostol

n=1,701

Readmission and hemorrhage

Kelly (2010)

RCT

13 to 20 weeks

No fetal abnormalities

Vacuum aspiration

n=62

Mifepristone followed by misoprostol

n=60

Hemorrhage, patient experience and mental health

Little (2015)

Observational study

17 to 24 weeks

Fetal anomalies, fetal death or previable preterm rupture of membranes (PPROM) without signs of spontaneous labor

D&E

n=130

Misoprostol alone or mifepristone followed by misoprostol

n=43

Risk of premature birth in following pregnancy

Sonalkar (2017)

Observational study

14 to 24 weeks

Induced abortion, preterm premature rupture of membranes, intrauterine fetal death, maternal health, fetal anomaly

D&E

n=343

Misoprostol

n=122

Readmission, blood transfusion, maternal death

Tufa (2021)

Observational study

13 to 20 weeks

Elective termination of pregnancy

D&E

n=60

Mifepristone followed by misoprostol

n=219

Uterine infection and patient experience

Turok (2007)

Observational study

13 to 24 weeks

Intrauterine fetal demise, fetal anomaly, fetal condition incompatible with life or severe maternal medical conditions. However, in the clinical D&E group, most women underwent elective termination of pregnancy (98%).

D&E

n=336 (n=83 in hospital; n=253 in clinic)

Induction (unspecified)

n=89

Readmission, blood transfusion, and uterine infection

Whitley (2011)

Observational study

13+0 to 23+6 weeks

Chromosomal or genetic abnormalities, structural abnormalities, fetal demise, maternal medical condition or preterm premature rupture of membranes

D&E

n=94

Prostaglandin induction (misoprostol, dinoprostone, oxytocin)

n=126

Blood transfusion, uterine infection, trombovenous events, and maternal death

D&E=dilatation and evacuation; RCT=randomized controlled trial

 

Results

 

1. Severe maternal morbidity

1.1. ICU admission

Not reported.

 

1.2. Readmission

Four studies reported hospital readmission (Autry, 2002; Kapp, 2021; Sonalkar, 2017; Turok, 2007).

 

Autry (2002) reported hospital readmission rate. For women receiving instrumental abortion (n=139), a mean rate of 1 (SD=0.7) was found as compared to 1 (SD=0.6) for women receiving medical abortion (n=158). No difference was found (MD=0.00, 95%CI -0.15 to 0.15). 

 

Kapp (2021) did not report any readmission for women either undergoing instrumental abortion (n=593) or receiving medical abortion (n=1,701).

 

Sonalkar (2017) reported that 3 of the 343 women (0.9%) who underwent instrumental abortion were readmitted as compared to 1 of the 121 women (0.8%) who received medical abortion (RR=1.06, 95%CI 0.11 to 10.08).

 

Turok (2007) reported that 20 of the 83 women (24%) who underwent Hospital D&E were readmitted as compared to 14 of the 89 women (16%) who received Hospital Induction (RR=1.53, 95%CI 0.83 to 2.83). When compared with a D&E at a private outpatient facility, 2 of the 253 women (1%) who underwent Clinic D&E were readmitted as compared to 14 of the 89 women (16%) who received Hospital Induction (RR=0.05, 95%CI 0.01 to 0.22).

 

1.3. Hemorrhage

Four studies reported hemorrhage (Chhetri, 2015; Jacques, 2021; Kelly, 2010; Turok, 2007). Only the RCTs of Chettri (2015) and Kelly (2010) were included.

 

Chhetri (2015) reported a mean blood loss of 69.6 mL (SD=11.4) for women undergoing instrumental abortion (n=66) as compared to 129.4 mL (SD=20.6) for women receiving medical abortion (n=75) (MD=-59.80, 95%CI -65.21 to -54.39).

Thirteen of the 75 women (17.3%) who underwent medical abortion had a retained placenta, for which manual placental removal was performed. There were no women with incomplete treatment or retained placenta in the group of women treated surgically.

 

Kelly (2010) reported hemorrhage defined as an estimated blood loss of >500 mL. Five of the 62 women (8%) undergoing instrumental abortion had a hemorrhage as compared to one of the 60 women (2%) receiving medical abortion (RR=4.48, 95%CI 0.58 to 40.21).

Five women in the medical abortion group (8.3%) underwent evacuation for retained products of conception.

 

1.4. Blood transfusion

Six studies reported hemorrhage that required blood transfusion (Autry, 2002; Chhetri, 2015; Kapp, 2021; Sonalkar, 2021; Turok, 2007; Whitely, 2011).  

 

Autry (2002) reported the rate of hemorrhage with transfusion. For women receiving instrumental abortion (n=139), a mean rate of 1 (SD=0.7) was found as compared to 1 (SD=0.6) for women receiving medical abortion (n=158). No difference was found (MD=0.00, 95%CI -0.15 to 0.15).

 

Chhetri (2015) reported that 2 of the 66 women (3%) who received instrumental abortion required transfusion as compared to 8 of the 75 women (11%) undergoing medical abortion (RR=0.28, 95%CI 0.06 to 1.29).

 

Kapp (2021) reported that 1 of the 593 women (0.2%) who underwent instrumental abortion had a hemorrhage and needed transfusion as compared to 6 of the 1,701 women (0.4%) who received medical abortion (RR=0.48, 95%CI 0.06 to 3.96).

 

Sonalkar (2017) reported that 2 of the 343 women (0.6%) who underwent instrumental abortion required a blood transfusion as compared to 3 of the 121 women (2.5%) who received medical abortion (RR=0.24, 95%CI 0.04 to 1.39).

 

Turok (2007) reported that 6 of the 83 women (7%) who underwent Hospital D&E required transfusion as compared to 1 of the 89 women (1%) who received Hospital Induction (RR=6.43, 95%CI 0.79 to 52.32). This difference is clinically relevant favoring medical abortion. When compared with a D&E at a private outpatient facility, two of the 253 women (1%) who underwent Clinic D&E required transfusion as compared to 1 of the 89 women (1%) who received Hospital Induction (RR=0.70, 95%CI 0.06 to 7.67).

 

Whitley (2011) reported that 1 of the 94 women (1%) who underwent D&E required transfusion as compared to 2 of the 126 (2%) of the women who received medical abortion (RR=0.67, 95%CI 0.06 to 7.28).

 

1.5. Uterine infection

Three studies reported uterine infection (Tufa, 2021; Turok, 2007; Whitley, 2011).

 

Tufa (2021) reported symptoms of pelvic infection. One of the 60 women (1.7%) who underwent instrumental abortion had symptoms of pelvic infection as compared to 21 of the 219 women (9.6%) who received medical abortion (RR=0.17, 95%CI 0.02 to 1.27).

 

Turok (2007) reported chorioamnionitis after initiating termination and endometritis.

One of the 83 women (1%) who underwent hospital D&E had chorioamnionitis as compared to 6 of the 89 women (7%) who received medical abortion (RR=0.18, 95%CI 0.02 to 1.45). When compared to clinical D&E, no women who underwent D&E at the clinic (n=253) had chorioamnionitis as compared to 6 of the 89 women (7%) who received medical abortion (RR=0.03, 95%CI 0.00 to 0.48).

Endometritis was experienced by 1 of the 83 women (1%) who underwent hospital D&E as compared to 4 of the 89 women (5%) who underwent medical abortion (RR=0.27, 95%CI 0.03 to 2.35). When compared to clinical D&E, 11 of the 253 women (4%) who underwent D&E at the clinic had endometritis as compared to 4 of the 89 women (5%) who received medical abortion (RR=0.97, 95%CI 0.32 to 2.96).

 

Whitley (2011) reported that 4 of the 94 women (4%) who underwent D&E had chorioamniotis/endometritis as compared to 10 of the 126 (8%) of the women who received medical abortion (RR=0.54, 95%CI 0.17 to1.66).

  

1.6. Sepsis

Chhetri (2015) reported that no sepsis occurred in either the instrumental abortion group (n=66) or the medical abortion group (n=75).

 

1.7. Trombovenous events

Two studies reported trombovenous events. The study of Jacques (2021) reported thromboembolism and Whitely (2011) reported pulmonary embolus.

 

Jacques (2021) reported that 1 of the 81 women (1%) who underwent medical abortion had a thromboembolism, while this was not experienced in women undergoing instrumental abortion (n=75) (RR=0.36, 95%CI 0.01 to 8.69).

 

Whitley (2011) reported pulmonary embolus. Only 1 of the 126 women (1%) who received medical abortion had a pulmonary embolus, while no cases were reported in the D&E group (n=94) (RR=0.45, 95%CI 0.02 to 10.82).

 

2. Late fertility and pregnancy effects  

2.1. Return of menstrual cycle

Not reported.

 

2.2. Fertility/Asherman

Not reported.

 

2.3. Risk of premature birth in following pregnancy

Little (2015) reported that 10 of the 130 women (7.7%) who underwent prior D&E had a preterm delivery as compared to 13 of the 43 women (30.2%) who underwent prior medical abortion (RR=0.25, 95%CI 0.12 to 0.54).

 

2.4. Risk of abnormal placentation in following pregnancy

Not reported.

 

3. Maternal death

Two studies reported maternal death (Sonalkar, 2017 (n=465); Whitley, 2011 (n=220)). Both studies did not report any maternal death in either the instrumental or medical abortion group.

 

4. Patient experiences

4.1. Satisfaction

Two studies reported satisfaction (Grimes, 2004; Kelly, 2010).

 

Grimes (2004) reported overall satisfaction at discharge measured on a five-point Likert scale with a score of 1 corresponding to very satisfied and a score of 5 corresponding to very dissatisfied. Women undergoing either D&E (n=9) or medical abortion with mifepristone-misoprostol (n=9) were very satisfied (median of 1 with IQR 1-1).

 

Kelly (2010) reported that 35 of the 36 women (97.2%) undergoing instrumental abortion were satisfied with the care during termination of pregnancy as compared to all 30 women who received medical abortion (RR=0.98, 95% CI 0.90 to 1.06).

 

4.2. Acceptability

Three studies reported acceptability (Grimes, 2004; Kelly, 2010; Tufa, 2021). Only the RCT of Grimes (2004) and Kelly (2010) were included.

 

Grimes (2004) reported if women would repeat the same method in the future on a five-point Likert scale with a score of 1 corresponding to yes (highly agree) and a score of 5 corresponding to no (highly disagree). Women undergoing either D&E (n=9) or medical abortion with mifepristone-misoprostol (n=9) highly agree with repeating the same method in the future (median of 1 with IQR 1-1). 

 

Kelly (2010) reported the amount of women that would choose the same method again. All 36 women undergoing instrumental abortion would choose the same method again as compared to 16 of the 30 women (53%) receiving medical abortion (RR=1.84, 95%CI 1.32 to 2.58).

 

5. Mental health

5.1 Post-traumatic stress

Kelly (2010) reported stress reactions at baseline and two weeks after treatment with the 15-item impact of events scale (IES). Each item can be scored with 0 (not at all), 1 (seldom), 3 (sometimes) and 5 (often). Women undergoing instrumental abortion (n=62) had a mean total IES score of 30.1 as compared to 36.8 for women receiving medical abortion (n=60). This study did not report standard deviations.

 

5.2 Depression

Two studies reported on depression (Kelly, 2010; Burgoine, 2015). Only the RCT of Kelly (2010) was included.

 

Kelly (2010) reported depression at baseline and two weeks after treatment with the HADS score for depression (HAD-D). The HAD-D is part of the HADS and consists of 7-items each rated between 0 and 3 (corresponding to score between 0 and 21). Women undergoing instrumental abortion (n=62) had a mean HAD-D score of 3.9 as compared to 5.0 for women receiving medical abortion (n=60). This study did not report standard deviations.

 

5.3   Anxiety

Kelly (2010) reported anxiety at baseline and two weeks after treatment with the HADS score for anxiety (HAD-A). The HAD-A is part of the HADS and consists of 7-items each rated between 0 and 3 (corresponding to score between 0 and 21, with higher scores related to more anxiety). Women undergoing instrumental abortion (n=62) had a mean HAD-A score of 6.5 as compared to 6.3 for women receiving medical abortion (n=60). This study did not report standard deviations.

 

5.4 Psychological morbidity

Kelly (2010) reported psychological distress at baseline and two weeks after treatment with the general health questionnaire (GHQ-12; corresponding to a score between 0 and 12, with higher scores related to more distress). Women undergoing instrumental abortion (n=62) had a mean GHQ-12 score of 2.1 as compared to 4.4 for women receiving medical abortion (n=60). This study did not report standard deviations.

 

5.5 Levels of grief

Burgoine (2005) reported the level of grief with the 33-item Perinatal Grief Scale (PGS) up to 12 months. Ongoing grief was defined as a score of 91 or more. For women undergoing D&E (n=22) the mean score was 73.3 (SD=17.1) as compared to 86.4 (SD=19.8) for women receiving IOL (n=27) (MD=-13.10, 95%CI -26.61 to 0.41).

 

5.6   Long-term coping

Not reported.

 

5.7   Adjustment

Not reported.

 

5.8   Doubt

Not reported.

 

5.9   Well-being

Not reported.

 

5.10 Relief

Not reported.

 

Level of evidence of the literature

According to GRADE, the level of evidence of randomized controlled trials start at high and for observational studies at low. 

 

1. Severe maternal morbidity

The level of evidence regarding the outcome measure ICU admission could not be assessed with GRADE.

 

The level of evidence regarding the outcome measure readmission started at low and was downgraded by one level to very low because of conflicting results (inconsistency) and the 95% confidence interval crossed the lines of no clinically relevant effect (imprecision).

 

The level of evidence regarding the outcome measure hemorrhage started at high and was downgraded by three levels to very low because of concerns about blinding and frequent loss to follow-up (-1, risk of bias), conflicting results (-1, inconsistency) and the 95% confidence interval crossed the lines of no clinically relevant effect (-1, imprecision).

 

The level of evidence regarding the outcome measure blood transfusion started at low and was downgraded by one level to very low because the 95% confidence interval crossed the lines of no clinically relevant effect (imprecision).

 

The level of evidence regarding the outcome measure uterine infection started at low and was downgraded by one level to very low because of concerns about the selection of participants (risk of bias) and the 95% confidence interval crossed the lines of no clinically relevant effect (imprecision).

 

The level of evidence regarding the outcome measure sepsis started at high and was downgraded by three levels to very low because no events occurred and the optimal information size was not achieved (-3, imprecision).

 

The level of evidence regarding the outcome measure trombovenous events started at low and was downgraded by one level to very low because the 95% confidence interval crossed the lines of no clinically relevant effect (imprecision).

 

2. Late fertility and pregnancy effects

The level of evidence regarding the outcome measure risk of premature birth in following pregnancy started at low and was downgraded by one level to very low because of concerns about the selection of participants (risk of bias) and the optimal information size was not achieved imprecision (imprecision).

 

The level of evidence regarding the outcome measures risk of abnormal placentation in following pregnancy, return of menstrual cycle and fertility/Asherman could not be assessed with GRADE.

 

3. Maternal death

The level of evidence regarding the outcome measure maternal death started at low and was downgraded with one level to very low because no events occurred (imprecision).

 

4. Patient experiences

The level of evidence regarding the outcome measure satisfaction started at high and was downgraded by three levels to very low because of concerns about blinding and frequent loss to follow-up (-1, risk of bias) and the 95% confidence interval crossed both lines of no clinically relevant effect (-2, imprecision).

 

The level of evidence regarding the outcome measure acceptability started at high and was downgraded by three levels to very low because of concerns about blinding and frequent loss to follow-up (-1, risk of bias), conflicting results (-1, consistency), and the optimal information size was not achieved (-1, imprecision).

 

5. Mental health

The level of evidence regarding the outcome measure post-traumatic stress, depression, anxiety and psychological morbidity started at high and was downgraded by three levels to very low because of concerns about blinding (-1, risk of bias), the optimal information size was not achieved and no measures of spread were reported (-2, imprecision).

 

The level of evidence regarding the outcome measure levels of grief started at low and was downgraded by one level to very low because the optimal information size was not achieved (imprecision).

 

The level of evidence regarding the outcome measures long-term coping, adjustment, doubt, well-being, and relief could not be assessed with GRADE.

A systematic review of the literature was performed to answer the following question:

What are the favorable and unfavorable effects of instrumental termination of pregnancy compared to medical termination of pregnancy in the second trimester of pregnancy?

 

P: Women with a second trimester termination of pregnancy
I:  Instrumental termination of pregnancy (vacuum aspiration, D&C (dilation and curettage), D&E (dilation and evacuation))
C: Medical termination of pregnancy (mifepristone, misoprostol, sulprostone)
O:

1. Severe maternal morbidity

1.1   ICU admission

1.2   Readmission

1.3   Hemorrhage

1.4   Blood transfusion

1.5   Uterine infection

1.6   Sepsis

1.7   Trombovenous events

2. Late fertility and pregnancy effects

2.1 Return of menstrual cycle

2.2 Fertility/Asherman

2.3 Risk of premature birth in following pregnancy

2.4 Risk of abnormal placentation in following pregnancy

3. Maternal death

4. Patient experience

4.1 Satisfaction

4.2 Acceptability

5. Mental health

5.1. Post-traumatic stress

5.2. Depression

5.3. Anxiety

5.4. Psychological morbidity

5.5. Levels of grief

5.6. Long-term coping

5.7. Adjustment

5.8. Doubt

5.9. Well-being

5.10. Relief

Relevant outcome measures

The guideline development group considered severe maternal morbidity and late fertility and pregnancy effects as critical outcome measures for decision making; and maternal death, patient experiences and mental health as important outcome measures for decision making.

 

The working group did not define the outcome measures but used the definitions used in the studies.

 

The guideline development group defined the following as a minimal clinically (patient) important difference:

  • Severe maternal morbidity: 10% difference in relative risk (0.91 ≤ RR ≥ 1.10 or -0.10 ≤ SMD ≥ 0.10)
    • Hemorrhage: > 1 L or 25% difference in relative risk (RR < 0.8 to > 1.25) for the dichtotomous outcome fluxus postpartum
  • Maternal death: 1% difference in relative risk (0.99 ≤ RR ≥ 1.01 or -0.01 ≤ SMD ≥ 0.01)
  • For the other outcomes, a 25% difference for dichotomous outcomes (RR < 0.8 or > 1.25) and 0.5 SD for continuous outcomes was defined as a minimal clinically (patient) important difference.

Search and select (Methods)

The databases Medline (via OVID) and Embase (via Embase.com) were searched with relevant search terms from 2000 until 17 February 2023 for systematic reviews and randomized controlled trials (RCTs) and until 3 May 2023 for observational studies. The detailed search strategy is depicted under the tab Methods. The systematic literature search resulted in 744 hits. Studies were selected based on the following criteria:

  • systematic review and/or meta-analysis, with detailed search strategy, risk of bias assessment, and results of individual studies available; randomized controlled trial (RCT) or observational study;
  • studies according to the PICO. Women with a second trimester termination of pregnancy (both early and late second trimester) receiving instrumental termination of pregnancy as an intervention, and medical termination of pregnancy as a comparison;
  • full-text English language publication;

Nineteen studies were initially selected based on title and abstract screening. After reading the full text, eight studies were excluded (see the table with reasons for exclusion under the tab Methods), and eleven studies were included. Two RCTs included in the systematic review of Schmidt-Hansen (2020) matching with the PICO were included (Grimes, 2004; Kelly, 2010) and complemented with the RCT of Chhetri (2015). In addition, nine observational studies (Autry, 2002; Burgoine, 2005; Jacques, 2020; Kapp, 2021; Little, 2015; Sonalkar, 2017; Tufa, 2021; Turok, 2008; Whitley, 2011) were included.

 

Results

Three RCTs and nine observational studies were included in the analysis of the literature. Important study characteristics and results are summarized in table 1 and the evidence tables. The assessment of the risk of bias is summarized in the risk of bias tables. No distinction could be made between early and late second trimester pregnancy as this was not reported separately in the studies.

 

When an RCT was available for a certain outcome measure, observational studies reporting the same outcome measure were not included because it was based on the best available evidence.

  1. Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol. 2002 Aug;187(2):393-7. doi: 10.1067/mob.2002.123887. PMID: 12193931.
  2. Burgoine GA, Van Kirk SD, Romm J, Edelman AB, Jacobson SL, Jensen JT. Comparison of perinatal grief after dilation and evacuation or labor induction in second trimester terminations for fetal anomalies. Am J Obstet Gynecol. 2005 Jun;192(6):1928-32. doi: 10.1016/j.ajog.2005.02.064. PMID: 15970853.
  3. Chhetri S, Pokharel H, Rijal R, Lama S. Assessment of the efficacy of different methods of second trimester abortion: an initial experience in eastern Nepal. JSAFOG. 2015 Sep;7(3):182-4.
  4. Chung JPW, Law TSM, Ng K, Ip PNP, Li TC. Intrauterine adhesion in ultrasound-guided manual vacuum aspiration (USG-MVA) versus electric vacuum aspiration (EVA): a randomised controlled trial. BMC Pregnancy Childbirth. 2024 Feb 14;24(1):135. doi: 10.1186/s12884-024-06328-y. PMID: 38355420; PMCID: PMC10865674.
  5. Dempsey A, Davis A. Medical management of early pregnancy failure: how to treat and what to expect. Semin Reprod Med. 2008 Sep;26(5):401-10. doi: 10.1055/s-0028-1087106. Epub 2008 Sep 29. PMID: 18825608.
  6. Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial. BJOG. 2004 Feb;111(2):148-53. doi: 10.1046/j.1471-0528.2003.00044.x-i1. PMID: 14723752.
  7. Hooker AB, Lemmers M, Thurkow AL, Heymans MW, Opmeer BC, Brölmann HA, Mol BW, Huirne JA. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update. 2014 Mar-Apr;20(2):262-78. doi: 10.1093/humupd/dmt045. Epub 2013 Sep 29. PMID: 24082042.
  8. Jacques L, Heinlein M, Ralph J, Pan A, Nugent M, Kaljo K, Farez R. Complication rates of dilation and evacuation and labor induction in second-trimester abortion for fetal indications: A retrospective cohort study. Contraception. 2020 Aug;102(2):83-86. doi: 10.1016/j.contraception.2020.04.018. Epub 2020 May 1. PMID: 32360665.
  9. Kapp N, Griffin R, Bhattarai N, Dangol DS. Does prior ultrasonography affect the safety of induced abortion at or after 13 weeks' gestation? A retrospective study. Acta Obstet Gynecol Scand. 2021 Apr;100(4):736-742. doi: 10.1111/aogs.14040. Epub 2020 Dec 19. PMID: 33185906; PMCID: PMC8246849.
  10. Kelly T, Suddes J, Howel D, Hewison J, Robson S. Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial. BJOG. 2010 Nov;117(12):1512-20. doi: 10.1111/j.1471-0528.2010.02712.x. Epub 2010 Sep 22. PMID: 20860598.
  11. Lemmers M, Verschoor MA, Hooker AB, Opmeer BC, Limpens J, Huirne JA, Ankum WM, Mol BW. Dilatation and curettage increases the risk of subsequent preterm birth: a systematic review and meta-analysis. Hum Reprod. 2016 Jan;31(1):34-45. doi: 10.1093/humrep/dev274. Epub 2015 Nov 2. PMID: 26534897.
  12. Little SE, Janiak E, Bartz D, Smith NA. Second trimester dilation and evacuation: a risk factor for preterm birth? J Perinatol. 2015 Dec;35(12):1006-10. doi: 10.1038/jp.2015.132. Epub 2015 Oct 22. PMID: 26491851.
  13. Saccone G, Perriera L, Berghella V. Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016 May;214(5):572-91. doi: 10.1016/j.ajog.2015.12.044. Epub 2015 Dec 29. PMID: 26743506.
  14. Schmidt-Hansen M, Lohr PA, Cameron S, Hasler E. Surgical or medical abortion of pregnancies between 13+0 and 23+6 weeks' gestation? A systematic review and new NICE national guidelines. BMJ Sex Reprod Health. 2020 Mar 17:bmjsrh-2019-200460. doi: 10.1136/bmjsrh-2019-200460. Epub ahead of print. PMID: 32184291.
  15. Sonalkar S, Ogden SN, Tran LK, Chen AY. Comparison of complications associated with induction by misoprostol versus dilation and evacuation for second-trimester abortion. Int J Gynaecol Obstet. 2017 Sep;138(3):272-275. doi: 10.1002/ijgo.12229. Epub 2017 Jun 23. PMID: 28585710.
  16. Tufa TH, Prager S, Wondafrash M, Mohammed S, Byl N, Bell J. Comparison of surgical versus medical termination of pregnancy between 13-20 weeks of gestation in Ethiopia: A quasi-experimental study. PLoS One. 2021 Apr 1;16(4):e0249529. doi: 10.1371/journal.pone.0249529. PMID: 33793655; PMCID: PMC8016219.
  17. Turok DK, Gurtcheff SE, Esplin MS, Shah M, Simonsen SE, Trauscht-Van Horn J, Silver RM. Second trimester termination of pregnancy: a review by site and procedure type. Contraception. 2008 Mar;77(3):155-61. doi: 10.1016/j.contraception.2007.11.004. Epub 2008 Jan 11. PMID: 18279684.
  18. Westendorp, I. C., Ankum, W. M., Mol, B. W., & Vonk, J. (1998). Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. Human reproduction (Oxford, England), 13(12), 3347-3350.
  19. Whitley KA, Trinchere K, Prutsman W, Quiñones JN, Rochon ML. Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes. Am J Obstet Gynecol. 2011 Oct;205(4):386.e1-7. doi: 10.1016/j.ajog.2011.07.028. Epub 2011 Jul 22. PMID: 22083061.

Evidence table for intervention studies

 

Research question: What are the favorable and unfavorable effects of instrumental termination of pregnancy compared to medical termination of pregnancy in the second trimester of pregnancy?

Study reference

Study characteristics

Patient characteristics 2

Intervention (I)

Comparison / control (C) 3

 

Follow-up

Outcome measures and effect size 4

Comments

Autry, 2002

Type of study:

Retrospective cohort study

 

Setting and country:

Two university hospitals in Milwaukee, US

 

Funding and conflicts of interest:

Not reported

 

Inclusion criteria:

Women who undergo dilation and evacuation or medical abortion between 14 and 24 weeks of gestation

 

Exclusion criteria:

Not reported

 

N total at baseline:

Intervention: 139

Control: 158

 

Important prognostic factors2:

Age ± SD:

I: 30.2 ± 7.5

C: 30.5 ± 6.4

 

Gestational age

I: 18.4 ± 2.2

C: 20.3 ± 2.0

 

Groups not comparable at baseline

 

Describe intervention (treatment/procedure/test):

D&E

 

 

Describe control (treatment/procedure/test):

Medical abortion (specifically misoprostol)

 

 

Length of follow-up:

Not reported

 

Loss-to-follow-up:

Not reported

 

Incomplete outcome data:

Not reported

 

Readmission (mean ± SD)

I: 1 ± 0.7

C: 1 ± 0.6

 

Hemorrhage requiring transfusion (mean ± SD)

I: 1 ± 0.7

C: 1 ± 0.6

 

 

 

Author’s conclusion

Dilation evacuation is the safest method of second-trimester abortion. Misoprostol is safer

than other methods for medical abortion. Maximal use of Laminaria will decrease complication rates in surgical abortion

 

Remarks

Ascertainment bias both in the identification of patients and in insufficient documentation. Complications may have occurred that were treated by

the referring physicians without the author’s knowledge

 

Burgoine, 2005

Type of study:

Prospective cohort study

 

Setting and country:

Oregon Health and Science University (OHSU) Hospital, US

 

Funding and conflicts of interest:

Not reported

 

Inclusion criteria:

English literate women between 18 and 45 years with diagnosis of fetal anomalies in second trimester choosing to terminate their pregnancy

 

Exclusion criteria:

Not reported

 

N total at baseline:

Intervention: 22

Control: 27

 

Important prognostic factors2:

Age ± SD:

I: 28.8 ± 7.1

C: 28.3 ± 5.9

 

Estimated gestational age

I: 19.2 ± 2.3

C: 20.4 ± 2.6

 

Groups comparable at baseline

 

Describe intervention (treatment/procedure/test):

D&E

 

D&E procedures were performed as day surgery cases under general anesthesia at OHSU

Hospital or at a local outpatient facility.

Describe control (treatment/procedure/test):

Induction of labor

 

IOL was performed at OHSU by using either vaginal misoprostol or intravenous oxytocin and labor analgesia

with intravenous opiates or epidural anesthesia as subjects desired

Length of follow-up:

12 months

 

Loss-to-follow-up:

I: 7 (32%)

C: 13 (48%)

Reason: did not return questionnaires

 

Incomplete outcome data:

For EPDS

I: 4 (27%)

C: 4 (29%)

 

Depression (Edinburgh

Postnatal Depression Scale (EPDS)

Mean score at 12 months

I: 6.91 ± 4.7

C: 8.80 ± 6.5

 

Grief (Perinatal Grief Scale (PGS)

Mean score at 12 months

I: 73.3 ± 17.1

C: 86.4 ± 19.8

 

Author’s conclusion

There is no significant difference in grief resolution among women who terminate a desired pregnancy by either medical or surgical abortion

 

Remarks

- High dropout rate à low number of participants

 

Chhetri, 2015

Type of study:

Prospective randomized control trial

 

Setting and country:

Department of Obstetrics and Gynecology

at the BP Koirala Institute of Health Sciences (BPKIHS)

in Dharan, which is a tertiary referral centre in eastern Nepal

 

Funding and conflicts of interest:

Nil source of support and no conflict of interest.

 

Inclusion criteria:

- Voluntary termination of intrauterine pregnancy
- Gestational age between 12 to 18 weeks based on the last menstrual period and on obstetric ultrasonography
- Singleton pregnancy
- Hemoglobin of
³ 10 gm/dL

 

Exclusion criteria:

- Twin pregnancies
- Gestational age >18 weeks
- Previous two cesarean section
- Previous uterine scar like myomectomy
- Patients with chronic diseases
- Chronic adrenal failure
- Prolong use of steroids
- Inherited prophyrias
- Asthma
- Bronchitis
- Anticoagulant disease
- Allergic to mifepristone or misoprostol
- Patients who have already taken the medication.

N total at baseline:

Intervention: 66

Control: 75

 

Important prognostic factors2:

Age ± SD:

I: 28.4 ± 6.6 years

C: 27.6 ± 7.6 years

 

Multigravida

I: 65%

C: 75%

 

Groups comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental abortion: cervical priming with misoprostol followed by dilatation and evacuation (D&E)

 

 

 

Describe control (treatment/procedure/test):

Medical abortion: mifepristone 200 mg followed by misoprostol 400 mcg vaginally or sublingually after admission until the patient expels the fetus. Max. 5 doses four hours apart

 

Length of follow-up:

Not reported.

 

Loss-to-follow-up:

Not reported

 

Incomplete outcome data:

Not reported

 

 

Hemorrhage

Blood loss in mL

I: 69.6 mL (SD=11.4)

C: 129.4 mL (SD=20.6)

MD=59.80, 95%CI -65.21 to
-54.39

 

Blood transfusion

I: 2/66 (3%)

C: 8/75 (11%)

RR=0.28, 95%CI 0.06 to 1.29

 

Sepsis

I: 0

C: 0

Author’s conclusion

Surgical method of second trimester abortion is more effective and safe procedure in experienced centers and as compared to medical methods. The complication rates are lower, and it also is more

cost-effective as it can be performed in an outpatient setting and does not require hospital admission.

 

Remarks

- Nepal population

- Voluntary termination

Grimes, 2004

 

Type of study:

Pilot randomized controlled trial

 

Setting and country:

University of North Carolina Hospitals, Chapel Hill, North Carolina.

 

Funding and conflicts of interest:

Not reported.

 

Inclusion criteria:

- English speaking
- Women ³18 years

- Fetal biparietal diameter of 26 to 46 mm (13.9–19.9 weeks of gestation)

- Women that experienced a fetal death and those having a fetus with congenital anomalies or chromosomal defects were also included

 

Exclusion criteria:

- Patients with a prior caesarean delivery or myomectomy

- Patients with medical conditions such as chronic renal failure or asthma

- Listed in package labelling as contraindications to use mifepristone or misoprostol

- Patients with known transportation difficulties relating to the abortion visits

- Patients unwilling to return or to be contacted by telephone or letter two weeks later in follow up

 

N total at baseline:

Intervention: 9

Control: 9

 

Important prognostic factors2:

Age (median [IQR])

I: 26 (24 to 28)

C: 25 (22 to 27)

 

Gestational age (median [IQR])

I: 18 (16 to 19)

C: 18 (17 to 18)

 

Groups comparable at baseline

 

 

 

 

Describe intervention (treatment/procedure/test):

Instrumental abortion: laminaria preparation followed by dilatation and evacuation (D&E)

 

Procedure:

Day 1: multiple laminaria

placed in cervix under paracervical anaesthesia with 20 cc of 0.25% bupivacaine

One or two days later:

abortion performed in an outpatient surgery suite by a second- or third-year resident physician

supervised by the principal investigator. The principal

investigator performed one D&E when no resident was

available. Light general anaesthesia without intubation was used for each D&E. Initially, laminaria were left in place

one night. Prophylactic

oral doxycycline was administered when laminaria insertion was performed.

 

Describe control (treatment/procedure/test):

Medical abortion: mifepristone followed by labour induction with misoprostol

 

Procedure:

Day 1: mifepristone 200 mg oral (under supervision in clinic)

Two days later to gynecology ward:
- Received prophylactic prochlorperazine and diphenoxylate

- Placing misoprostol 800 mcg (four tablets) vaginally
- Misoprostol 400 mcg orally every 3 hours, to a maximum of four oral doses, until abortion occurs.

- Received a continuous infusion of morphine

with a patient-controlled analgesia system

- Received prophylactic

oral doxycycline at administration of misoprostol

 

If the placenta did not spontaneously pass within 2 hours of the fetus, the

participant was taken to the treatment room for placental

removal.

 

 

Length of follow-up:

Two weeks.

 

Loss-to-follow-up:

I: 4 (44%)

C: 5 (56%)

 

Incomplete outcome data:

Not reported.

 

Satisfaction (median [IQR])

I: 1 [1 to 1]

C: 1 [1 to 1]

*1 is very satisfied, 5 is very unsatisfied

 

Repeat same method (median [IQR])

I: 1 [1 to 1]

C: 1 [1 to 1]

*1 is highly agree, 5 is highly disagree

 

Author’s conclusion

The authors findings concerning acceptability and adverse events should be considered hypothesis generating; they may prove useful in planning a larger randomised controlled trial. Such a trial will be difficult to mount in the US. Hence, we suggest that it be done in a setting where labour-induction abortion is the norm.

 

Remarks

- Trial stopped at one year because of slow enrolment

- Small sample size

- Participants differed from those who declined enrolment

- Poor follow-up rate at two weeks 

Jacques, 2021

Type of study:

Retrospective cohort

 

Setting and country:

Froedtert Hospital in Milwaukee, Wisconsin (US)

 

Funding and conflicts of interest:

This research did not receive any specific grant from funding agencies

in the public, commercial, or not-for-profit sectors. The authors declare that they have no known

competing financial interests or personal relationships that could have appeared to

influence the work reported in this paper.

Inclusion criteria

Women who had a second trimester abortion for fetal anomaly or demise between 14 weeks 0 days and 23 weeks 6 days

 

Exclusion criteria

- PPROM

- Maternal cardiac disease

- Selective twin reduction

- Didn’t receive mifepristone prior to labor induction

- Received mifepristone prior to D&E

- Data was not entered in electronic medical records

- Maternal cancer

- Previously included in study

- Chorioamnionitis

- Indication for termination was not fetal anomaly or demise

 

N total at baseline:

Intervention: 75

Control: 81

 

Important prognostic factors2:

Age (median (range))

I: 32 (21–45)

C: 29 (18–44)

 

Gestational age (median (range))

I: 17+0 (14+0–23+1)

C: 20+5 (15+4–23+5)

 

Groups comparable at baseline

 

Describe intervention (treatment/procedure/test):

D&E  

 

D&E procedures were routinely performed in the hospital operating room under moderate sedation and paracervical block with

vasopressin. Second- or fourth-year residents performed the procedure

with ultrasound guidance under direct faculty supervision. Patients received doxycycline 100 mg orally within 1 hour of the procedure start time and 200 mg orally in the recovery room postoperatively as antibiotic prophylaxis. Surgeons provided cervical preparation with misoprostol 400 mcg buccally 2–4 hours preoperatively for patients under 18 weeks’ gestation and overnight osmotic dilators at 18 or more weeks gestation

Describe control (treatment/procedure/test):

Mifepristone and misoprostol

 

Labor induction abortions were routinely performed in the

labor and delivery unit using mifepristone 200 mg orally 24 to 48 hours prior to admission. Patients typically received misoprostol 800 mcg vaginally at admission followed by 400 mcg vaginally or buccal every three hours until delivery (maximum of 5 doses). After delivery of the fetus, providers typically allowed up to 6 hours for placental delivery in the absence of infection or hemorrhage, with provision of an additional misoprostol 400 mcg vaginally while awaiting placental expulsion if more than three hours elapsed since the last dose. Prophylactic antibiotics were not routinely

administered. Pain control options included intravenous opioid medications and neuraxial anesthesia.

Length of follow-up:

Not reported.

 

Loss-to-follow-up:

Not reported

 

Incomplete outcome data:

Demographic variables were missing

Hemorrhage (500 cc or greater)

I: 1/75 (1%)

C: 2/81 (3%)

RR=0.54, 95%CI 0.05 to 5.83

 

Thromboembolism

I: 0/75

C: 1/81 (1%)

RR=0.36, 95%CI 0.01 to 8.69

 

 

Author’s conclusion

There was no difference in complication rates between the D&E group and the labor induction group.

 

Remarks

- Findings may not be generalizable

- Not control for variations in D&E and labor induction treatment due to surgeon preference

- Selection bias

- Physician procedure bias

- Demographic variables missing

Kapp, 2021

 

Type of study:

Retrospective chart review

 

Setting and country:

Eight hospitals in seven different districts in Nepal

 

Funding and conflicts of interest:

Funded by Ipas (USA). No conflicts of interest reported

 

Inclusion criteria

All women undergoing an abortion at or after 13 weeks’ gestation with no upper gestational age limit, either by medical or surgical means, where at least some primary or secondary outcomes were recorded

 

Exclusion criteria

Not reported

 

N total at baseline:

Intervention: 1,701

Control: 593

Important prognostic factors2:

Gestational age >25 weeks

I: 0

C: 21 (3.5%)

 

Groups not comparable at baseline

 

 

Describe intervention (treatment/procedure/test):

D&E

 

Removal of pregnancy using forceps and aspiration techniques after preparing/dilating the cervix

Describe control (treatment/procedure/test):

Medical abortion with mifepristone and misoprostol

Length of follow-up:

Not reported.

 

Loss-to-follow-up:

Not reported

 

Incomplete outcome data:

Missing data was reported but not for outcomes of interest

Readmission

No cases

 

Blood transfusion

I: 1 (0.2%)

C: 6 (0.4%)

 

 

 

Author’s conclusion

This study confirms low complication rates among women having an abortion ≥13 weeks’ gestation in healthcare facilities. Settings without universal availability of ultrasound may still maintain low, comparable complication rates.

 

Remarks

- Limitations related to limited reporting in medical records

- Delayed complications such as infection were not systematically captured in this chart review, as women may have sought care in different settings after discharge

 

Kelly, 2010

Type of study:

Randomized controlled trial

 

Setting and country:

Large UK tertiary center

 

Funding and conflicts of interest:

This trial was undertaken with funding from the University of Newcastle upon Tyne. No conflicting interests to disclose.

 

Inclusion criteria

- Women accepted for termination of pregnancy under clause C of the human Fertilisation and Embryology Act (1990) amendment of the Abortion Act (1967), with pregnancies between 13 + 0 and 19 + 6 weeks of gestation at the time of abortion
- Women under 16 years of age were eligible for inclusion if deemed Fraser competent by the clinical practitioner, and where a parent or guardian was present and also willing to give written consent

- Women with a history of previous caesarean section were not excluded

 

Exclusion criteria

- Fetal congenital abnormality

- Medical disease precluding medical termination of pregnancy

- Women who were unable to speak English

 

N total at baseline:

Intervention: 62

Control: 60

 

Important prognostic factors2:

Age (mean (SD))

I: 23.5 (5.8)

C: 23.9 (6.3)

 

Gestational age (mean (SD))

I: 15.1 (1.9)

C: 14.7 (1.6)

 

Groups comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental termination of pregnancy with vacuum aspiration

 

Admitted to the gynecological day unit on the morning of the procedure.

  • Nulliparous and multiparous women ³17 weeks: primed with Gemeprost 1 mg vaginally 3 and 6 hours prior to procedure
  • Multiparous women between 13 + 0 and 16 + 6 weeks: primed with Gemeprost 1 mg vaginally 3 hours prior to procedure

Performed under general anaesthesia by one experienced surgeon.

 

Gestational age was confirmed on the operating table prior to cervical dilatation by ultrasound measurement of the BPD.

  • Cases between 13 + 0 and 13 + 6 weeks: progressively dilated to 13 mm using Hegar graded cervical dilators. Vacuum aspiration was performed using a 12-mm aspiration curette.
  • Cases between 14 + 0 and 14 + 6 weeks: dilated to 15 mm and vacuum aspiration was performed using a 14-mm aspiration curette. Complete evacuation of products of conception was confirmed by ultrasound and, where necessary, residual products were removed with sponge forceps under ultrasound guidance.
  • Cases of 15 + 0 or more: progressively dilated to a cervical diameter in mm equivalent to the gestational age in weeks using Hegar graded cervical dilators. Products of conception were removed using Sopher’s forceps under ultrasound guidance. Routine perioperative uterotonic agents were not used. Intravenous oxytocin (5 units) was administered in cases with persistent post-evacuation bleeding

 

All women received metronidazole 1 g rectally at the time of abortion.

 

Describe control (treatment/procedure/test):

Medical termination of pregnancy

 

Received mifepristone

200 mg orally and attend the gynaecological day unit at 8 a.m. 36–48 hours later. Misoprostol 800 mg was administered vaginally followed by 400 mg vaginally

or orally (depending on level of vaginal bleeding) every 3 hours up to a maximum of four doses.

 

If abortion had not occurred by midnight a further dose of mifepristone 200 mg orally was administered, followed by gemeprost 1 mg vaginally 3-hourly from 8 a.m. up to a

maximum of five doses.

 

If abortion had still not occurred by 8 a.m. the following morning the medical abortion was deemed to have failed and surgical abortion was arranged.

 

In all cases expelled products were examined to confirm that they were complete.

- Where this was uncertain, an ultrasound scan was performed to confirm the uterus was empty.

- Cases where the placenta was retained after expulsion of the fetus (confirmed by speculum examination) without significant bleeding were managed with a further dose of prostaglandin.

- Failure to pass the placenta after a further 4 hours was managed with surgical evacuation of retained products.

 

All women received periabortion antibiotic prophylaxis with doxycycline 100 mg orally twice daily, commencing on the day prior to abortion.

Length of follow-up:

Two weeks.

 

Loss-to-follow-up:

I: 22 (35%)

C: 22 (37%)

Reason: did not attend follow-up clinic or return postal questionnaires

 

Incomplete outcome data:

For outcome measures GHQ and HAD:

I: 5 (8%)

C: 12 (20%)

 

Hemorrhage (estimated blood loss of >500 mL)

I: 5/62 (8%)

C: 1/60 (2%)

RR=4.48, 95%CI 0.58 to 40.21

 

Mental health

Mean IES-T

I: 30.1

C: 36.8

MD=-6.7

 

GHQ-12

I: 2.1

C: 4.4

*MD=-2.6

 

Anxiety (HAD-A)

I: 6.5

C: 6.3

*MD=0

 

Depression (HAD-D)

I: 3.9

C: 5.0

*MD=0.9

 

*adjusted for those at baseline

 

Satisfaction

Would choose same method again

I: 100%

C: 53%

MD=47%

 

Satisfied with care during termination of pregnancy

I: 35 (97.2%)

C: 29 (100%)

 

 

Author’s conclusion

Randomised trials of women requesting mid-trimester termination of pregnancy are challenging. Women found surgical termination of pregnancy less painful and more acceptable than medical termination of pregnancy

 

Remarks

- Proposed sample size was not achieved

- Missing data

Little, 2015

Type of study:

Retrospective chart review

 

Setting and country:

Two clinical sites (large, urban, tertiary academic hospital and neighboring, private, general gynecology practice) at Boston, US

 

Funding and conflicts of interest:

Financial support by department funds. The authors declare no conflict of interest.

 

Inclusion criteria

Women who underwent a second trimester pregnancy termination at 17 to 24 weeks of gestation for fetal anomalies, fetal death or previable preterm rupture of membranes (PPROM) without signs of spontaneous labor, such as cervical dilation

 

Exclusion criteria

Women with severe maternal disease

 

N total at baseline:

Intervention: 130

Control: 43

 

Important prognostic factors2:

Age (median (25-75%))

I: 34.8 (31.8 to 37.6)

C: 31.6 (25.3 to 37.1)

 

Gestational age in days (median (25-75%))

I: 132 (127 to 141)

C: 144 (132 to 158)  

 

Groups not comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental abortion with D&E

 

D&E was performed under ultrasound guidance following 1 to 2 days of cervical preparation with laminaria. The number

and type of laminaria was at the providers’ discretion

Describe control (treatment/procedure/test):

Induction of labor

 

Labor inductions may have used laminaria as well (at the attending clinician’s discretion)

and were performed through high-dose misoprostol alone (prior to 2010) or through mifepristone and high-dose misoprostol after an institutional protocol change. The exact medication protocol was at the provider’s discretion, however, the most commonly used regimen was 200 mcg of mifepristone on the day prior to induction (after 2010) followed the next

day by 400 to 600 mcg of misoprostol (oral or buccal) loading dose, then 400 to 600 mcg every 3 to 6 h (not exceeding 3200 mcg in 24 h). Fetocidal agents were used in some but not all of the procedures at the patients’ and providers’ discretion.

Length of follow-up:

Not reported

 

Loss-to-follow-up:

No loss to follow-up

 

Incomplete outcome data:

No missing data

Preterm delivery

I: 10/130 (7.7%)

C: 13/43 (30.2%)

RR=0.25, 95%CI 0.12 to 0.54

Author’s conclusion

We did not find that D&E was a risk factor for preterm delivery when compared with women with a prior IOL or national rates.

 

Remarks

Potential for residual confounding and potential inaccuracies from chart-reviewed data

Sonalkar, 2017

Type of study:

Retrospective cohort study

Setting and country:

University of

California—Los Angeles Medical Center, Los Angeles, CA, USA

 

Funding and conflicts of interest:

Source of funding not reported. One author is consultant for WHO, the other authors have no conflicts of interest 

 

Inclusion criteria

Women who underwent uterine evacuation between 14 and 24 weeks of pregnancy

 

Exclusion criteria

Not reported

 

N total at baseline:

Intervention: 343

Control: 122

 

Important prognostic factors2:

Age (mean ± SD)

I: 26 ± 7

C: 27 ± 7

 

Length of pregnancy (mean ± SD)

I: 19 ± 3

C: 20 ± 2

  

Groups not comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental abortion with D&E

 

D&E was performed after 1–2 days of cervical preparation with

laminaria.

Describe control (treatment/procedure/test):

Induction of labor

 

Medical induction was performed with serial doses of misoprostol (400 μg), applied vaginally every 4–6 hours.

Length of follow-up:

Not reported

 

Loss-to-follow-up:

No loss to follow-up

 

Incomplete outcome data:

One data value was missing for medical induction group

 

Readmission

I: 3 (0.9%)

C: 1 (0.8%)

RR=1.06, 95%CI 0.11 to 10.08

 

Blood transfusion

I: 2 (0.6%)

C: 3 (2.5%)

RR=0.24, 95%CI 0.04 to 1.39

 

Maternal death

I: 0

C: 0

Author’s conclusion

Although D&E resulted in fewer overall complications as compared with medical induction, the rate of serious complications did not differ between the two procedures.

 

Remarks

- Potential for selection bias
- Lack of demographic information.

Tufa, 2021

Type of study:

Quasi-experimental study

 

Setting and country:

Saint Paul’s Hospital Millennium Medical College (SPHMMC), a tertiary referral and teaching hospital in Addis Ababa, Ethiopia.

 

Funding and conflicts of interest:

The research received a grant from Center for International Reproductive Health Training (CIRHT).

The authors have declared

that no competing interests exist.

 

Inclusion criteria:

Women with a gestational age between 13 and 20 weeks confirmed with ultrasound with an age ³18 years willing to provide informed consent for the study and had a working phone and willingness to be contacted for a follow-up questionnaire 2 weeks after the procedure

 

Exclusion criteria:

Not fulfil any of the inclusion criteria

 

N total at baseline:

Intervention: 60

Control: 219

 

Important prognostic factors2:

Age (18-25)

I: 38 (63.3%)

C: 176 (80.4%)

 

Gestational age (18 to 20.6 weeks)

I: 23 (38.3%)

C: 104 (47.5%)

  

Groups not comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental abortion with D&E

 

Received mifepristone 200 mg orally with or without intracervical laminaria and appointed to return the next day for surgical abortion

 

Those with advanced gestational age (>16 weeks) receive laminaria on the same day they receive mifepristone. Patients under 16 weeks gestational age received sublingual or vaginal misoprostol 400 mcg 2 hours prior to the procedure.

Describe control (treatment/procedure/test):

Medical abortion

 

Mifepristone 200 mg orally on day 1 and are appointed to return to SPHMMC 24–

48 hours later for admission and sublingual or vaginal misoprostol administration

 

 

Length of follow-up:

2 weeks

 

Loss-to-follow-up:

No loss to follow-up

 

Incomplete outcome data:

No missing data

Symptoms of pelvic infection

I: 1 (1.7%)

C: 21 (9.6%)

RR=0.17, 95%CI 0.02 to 1.27

 

Would recommend to others

I: 59 (98.3%)

C: 184 (84.0%)

RR=1.17, 95%CI 1.10 to 1.25

Author’s conclusion

There is no difference in safety between surgical and medical methods of abortion. Surgical abortion can be used as a safe and effective alternative to medical abortion and should be offered equivalently with medical abortion, per the patient’s preference.

 

Remarks

- Selection bias

Turok, 2007

Type of study

Retrospective cohort study

 

Setting and country:

University of Utah

Health Sciences Center (for hospital D&E and hospital induction) and Utah Women's Clinic (for clinic D&E)

 

Funding and conflicts of interest:

There was no funding

support for this investigation. No conflicts of interest reported.

 

Inclusion criteria:

Women with a termination of pregnancy between 13 and 24 weeks of gestation at University of Utah and from 13 to 21 weeks of gestation for Utah Women’s Clinic.

 

Exclusion criteria:

Not reported.

 

N total at baseline:

Intervention: 336    I1: 83 hospital D&E   

I2: 253 clinic D&E

Control: 89

 

Important prognostic factors2:

Maternal age (mean (SD))

I: 28.65 (7.66)

I2: 23.78 (6.54)

C: 27.01 (6.94)

 

Gestational age (mean (SD))

I: 16.45 (2.16)

I2: 16.45 (2.37)

C: 18.79 (2.22)

  

Groups not comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental abortion with D&E

 

Hospital D&Es were performed by obstetrics and

gynaecology residents under the supervision of an attending physician. Patients had laminaria inserted on the day prior to

surgery in order to prepare the cervix. Between one and three sets of laminaria were inserted depending upon gestation. Misoprostol was not used for cervical dilation during the study period. The procedure was performed under general anesthesia and with ultrasound guidance in one of the main

hospital operating rooms. Patients did not uniformly receive prophylactic antibiotics.

 

Patients in the Clinic D&E group at 13–14 weeks gestation had procedures performed with a lower

uterine field block for anesthesia but without cervical preparation. At 15–21 weeks gestation, patients had laminaria placed in the cervical canal 24–36 h prior to the procedures, which were done under ultrasound guidance.

Intravenous narcotics and lower uterine field block with a combination of bupivacaine and lidocaine were used for anesthesia. Patients at all gestations received postoperative

doxycycline, 100 mg po bidx7 days in the Clinic D&E

group. A single practitioner with >20 years of experience performed all procedures at UWC.

 

Describe control (treatment/procedure/test):

Medical abortion

 

Patients in the Hospital Induction group had labor initiated with varying doses of misoprostol or prostaglandin E2 (PGE2). Patients were admitted to the hospital and offered intravenous analgesia or epidural anesthesia. Deliveries were performed by an obstetrics and gynecology resident and/or attending physician.

Length of follow-up:

Not reported

 

Loss-to-follow-up:

No loss to follow-up

 

Incomplete outcome data:

No missing data

Readmission

I1: 20 (24%)

I2: 2 (1%)

C: 14 (16%)

 

Estimated blood loss (mean (SD)) (mL)

I1: 415.06 (355.25)

I2: 78.63 (191.79)

C: 326.53 (327.55)

 

Blood transfusion

I1: 6 (7%)

I2: 2 (1%)

C: 1 (1%)

 

Chorioamnionitis

I1: 1 (1%)

I2: 0

C: 6 (7%)

 

Endometritis

I1: 1 (1%)

I2: 11 (4%)

C: 4 (5%)

Author’s conclusion

Second trimester terminations of pregnancy by D&E in well-selected patients in a dedicated outpatient facility can be safer and less expensive than hospital-based D&E or induction of labor.

 

Remarks

- Under-reporting of complications

- Use of multiple providers

Whitley, 2011

Type of study

Retrospective cohort study

 

Setting and country:

Lehigh Valley Health Network

(Allentown, PA)

 

Funding and conflicts of interest:

Source of funding not reported. The authors report no conflict of interest

 

Inclusion criteria

All women undergoing planned midtrimester uterine evacuation procedure between 13+0 and 23+6 weeks

 

Exclusion criteria

- Women in active labor and/or advanced cervical dilation during the initial evaluation

- Pre-existing

Chorioamnionitis

- Pregnancies

outside the gestational age range of interest

 

N total at baseline:

Intervention: 94

Control: 126

 

Important prognostic factors2:

Maternal age (mean ± SD)

I: 32.8 ± 7.0

C: 29.1 ± 6.0

 

Median gestational age at procedure

I: 18 (13 to 23)

C: 20 (15 to 23)

  

Groups not comparable at baseline

 

Describe intervention (treatment/procedure/test):

Instrumental abortion with D&E

 

D&E is routinely performed as an outpatient procedure in the operating room under continuous ultrasound guidance by experienced

providers. Cervical ripening with laminaria is used for all patients undergoing D&E greater than 16 weeks’ gestation and for select patients prior to 16 weeks

 

 

Describe control (treatment/procedure/test):

Medical abortion with prostaglandin

 

Induction is performed as an inpatient procedure with vaginal misoprostol or

dinoprostone. Misoprostol is used most often as the first-line agent. The regimen is at the discretion of the provider, typically misoprostol 200-400 mg every 3-4 hours per vagina (using 100 or 200 mg tablets) or dinoprostone suppository 20 mg per vagina every 3 hours. Oxytocin augmentation is occasionally used. The provider may switch agents if the patient does not appear to be responding to the initial agent, usually after multiple doses. In general, induction agents are administered until delivery of both the fetus and the placenta.

Length of follow-up:

Not reported

 

Loss-to-follow-up:

No loss to follow-up

 

Incomplete outcome data:

No missing data

Blood transfusion

I: 1 (1%)

C: 2 (2%)

RR=0.67, 95%CI 0.06 to 7.28

 

Amnionitis/endometritis

I: 4 (4%)

C: 10 (8%)

RR=0.54, 95%CI 0.17 to 1.66

 

Pulmonary embolus

I: 0 (0%)

C: 1 (1%)

RR=0.45, 95%CI 0.02 to 10.82

Author’s conclusion

Midtrimester D&E is associated with fewer complications than prostaglandin induction.

 

Remarks

- Information or selection bias

- Insufficient power

 

 

Risk of bias table for intervention studies (RCTs)

 

Research question: What are the favorable and unfavorable effects of instrumental termination of pregnancy compared to medical termination of pregnancy in the second trimester of pregnancy?

Study reference

 

(first author, publication year)

Was the allocation sequence adequately generated?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Definitely yes

Probably yes

Probably no

Definitely no

Was the allocation adequately concealed?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Definitely yes

Probably yes

Probably no

Definitely no

Blinding: Was knowledge of the allocated

interventions adequately prevented?

 

Were patients blinded?

 

Were healthcare providers blinded?

 

Were data collectors blinded?

 

Were outcome assessors blinded?

 

Were data analysts blinded?

 

Definitely yes

Probably yes

Probably no

Definitely no

Was loss to follow-up (missing outcome data) infrequent?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Definitely yes

Probably yes

Probably no

Definitely no

Are reports of the study free of selective outcome reporting?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Definitely yes

Probably yes

Probably no

Definitely no

Was the study apparently free of other problems that could put it at a risk of bias?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Definitely yes

Probably yes

Probably no

Definitely no

Overall risk of bias

If applicable/necessary, per outcome measure

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOW

Some concerns

HIGH

 

Chhetri, 2015

Definitely yes;

 

Reason: Computer-generated randomization.

No information

Probably no;

 

Reason: No information provided but blinding of patients not possible.

Probably yes;

 

Reason: No loss to follow-up reported.

Probably no;

 

Reason: Not all outcomes reported in methods section were described under results.

 

Probably yes;

 

Reason: No other problems noted

Some concerns

Grimes, 2004

Definitely yes;

 

Reason: The randomisation

used random permuted blocks with block sizes of 4, 6, 8 and 12, randomly varied. A computer random number generator selected the block sizes and sequences.

 

Definitely yes;

 

Reason: Method indicator cards inside sequentially numbered, opaque, sealed envelopes.

Definitely no;

 

Reason: Neither participants nor investigators were blinded as to treatment assigned.

Probably no;

 

Reason: Loss to follow-up was frequent but similar between both groups.

Probably yes;

 

Reason: All relevant outcomes were reported.

Probably no;

 

Reason: Participants differed from those who declined enrolment and trial was stopped at one year because of slow enrolment (resulting in small sample sizes)

High

Kelly, 2010

Definitely yes;

 

Reason: Computer-generated randomisation table was used.

Definitely yes;

 

Reason: Sequentially numbered, sealed and opaque envelopes were prepared by a medical statistician who was not involved in the clinical care of the women.

 

Probably no;

 

Reason: No information provided but blinding of patients not possible.

Probably no;

 

Reason: Loss to follow-up was frequent but similar between both groups.

Probably yes;

 

Reason: All relevant outcomes were reported.

Probably no;

 

Reason: Proposed sample size not achieved and incomplete outcome data.

Some concerns

 

  

Risk of bias table for interventions studies (cohort studies) 

Author, year

Selection of participants

 

Was selection of exposed and non-exposed cohorts drawn from the same population?

Exposure

 

 

Can we be confident in the assessment of exposure?

 

Outcome of interest

 

Can we be confident that the outcome of interest was not present at start of study?

 

Confounding-assessment

 

Can we be confident in the assessment of confounding factors? 

Confounding-analysis

 

Did the study match exposed and unexposed for all variables that are associated with the outcome of interest or did the statistical analysis adjust for these confounding variables?

Assessment of outcome

 

Can we be confident in the assessment of outcome?

Follow up

 

 

Was the follow up of cohorts adequate? In particular, was outcome data complete or imputed?

 

 

Co-interventions

 

Were co-interventions similar between groups?

Overall Risk of bias

 

 

 

 

 

 

 

 

 

 

 

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Definitely yes, probably yes, probably no, definitely no

Low, Some concerns, High

Autry, 2002

Probably yes;

 

Reason: Both groups were selected in same university hospitals.

 

Probably yes;

 

Reason: Patient lists were compiled from labor and delivery records, operating room records, ICD-coding and departmental records.

 

Probably yes;

 

Reason: Outcomes related to received procedure.

Probably yes;

 

Reason: Confounding factors obtained from medical records.

Probably yes;

 

Reason: Study adjusted for variables.

Probably no;

 

Reason: Outcome derived from medical records but could be insufficiently documented.

Probably yes;

 

Reason: No missing data was reported.

Probably yes;

 

Reason: No other interventions.

Low

Burgoine, 2005

Probably yes;

 

Reason: Participants were selected from the same institute.

 

Probably yes;

 

Reason: Participants were choosing their own treatment. 

Probably no;

 

Reason: Depression could be present before start of the study.

 

Probably yes;

 

Reason: Demographic data was collected at enrollment.

Probably no;

 

Reason: No adjustment for confounders. 

Probably yes;

 

Reason: Validated questionnaires were used.

Probably no;

 

Reason: Drop-out rate was high but similar in both groups.

 

Probably yes;

 

Reason: No other interventions.

Some concerns

Jacques, 2021

Probably yes;

 

Reason: Both groups were selected from the same university hospital.

 

Probably yes;

 

Reason: Used an existing departmental abortion procedure database to identify patients

 

Probably yes;

 

Reason: Outcomes related to received procedure.

Probably yes;

 

Reason: Confounding factors obtained from medical records.

Probably no;

 

Reason: No adjustment for confounders. 

Probably yes;

 

Reason: Outcome derived from medical records.

Probably no;

 

Reason: Demographic variables were missing. 

Probably yes;

 

Reason: No other interventions.

Some concerns

Kapp, 2021

Probably yes;

 

Reason: Both groups were selected from the same hospitals.

 

Probably yes;

 

Reason: Logbook of abortion cases maintained by each hospital was used.

 

Probably yes;

 

Reason: Outcomes related to received procedure.

Probably yes;

 

Reason: Confounding factors obtained from medical records.

Probably yes;

 

Reason: Some adjustment was performed.  

Probably yes;

 

Reason: Outcome derived from medical records.

Probably yes;

 

Reason: No missing data for outcomes of interest.

Probably yes;

 

Reason: No other interventions.

Low

Little, 2015

Probably no;

 

Reason:

Women who received induction of labor (medical abortion) were selected from a tertiary care center while women who underwent instrumental abortion were selected from tertiary and private clinics.

 

Probably yes;

 

Reason:

Medical charts were used.

Probably yes;

 

Reason: Outcome related to received procedure.

Probably yes;

 

Reason: Confounding factors obtained from electronic database.

Probably yes;

 

Reason: Some adjustment was performed.

Probably yes;

 

Reason: Outcome derived from electronic database.

Probably yes;

 

Reason: No missing data.

Probably yes;

 

Reason: No other interventions

Some concerns

Sonalkar, 2017

Probably yes;

 

Reason: Both groups were selected from the same hospital by reviewing records.

 

Probably yes;

 

Reason: Extracted from medical records via ICD, Current Procedural Terminologycodes, and operating room logs.

 

Probably yes;

 

Reason: Outcomes related to received procedure.

Probably yes;

 

Reason: Confounding factors obtained from patient medical records.

Probably yes;

 

Reason: Study adjusted for variables.

Probably yes;

 

Reason: Outcome derived from medical records.

Probably yes;

 

Reason: Only one data value was missing

Probably yes;

 

Reason: No other interventions

Low

Tufa, 2021

Probably yes;

 

Reason: Both groups were selected from the same hospital.

 

Probably yes;

 

Reason: Participants were choosing their own treatment. 

Probably yes;

 

Reason: Outcomes related to received procedure.

Probably yes;

 

Reason: Baseline

sociodemographic and clinical information were collected upon admission to the hospital.

 

Probably yes;

 

Reason: Study adjusted for variables.

Probably yes;

 

Reason: Outcomes derived from provider’s note in the clinical chart and questionnaires or contact via phone.

 

Probably yes;

 

Reason: No missing data.

Probably no;

 

Reason: All surgical procedures received prophylactic antibiotics.

High

Turok, 2007

 

Probably no;

 

Reason:

Women were selected from university hospital and outpatient facility.

 

Probably yes;

 

Reason: Derived from hospital records. 

Probably yes;

 

Reason: Most outcomes related to received procedure and women with pre-existing infection were excluded.

 

Probably yes;

 

Reason: Confounding factors obtained from patient medical records.

Probably yes;

 

Reason: Study adjusted for variables.

Probably yes;

 

Reason: Outcomes derived from medical records.

Probably yes;

 

Reason: No missing data.

Probably yes;

 

Reason: No other interventions.

High

Whitley, 2011

Probably yes;

 

Reason: Both groups were selected from the same institution. 

 

Probably yes;

 

Reason:

Patients were identified by procedure (Current Procedural Terminology) and diagnosis (ICD) codes. Besides, Report of Induced Termination of Pregnancy forms and delivery logs were reviewed.

 

Probably yes;

 

Reason: Most outcomes related to received procedure and exclusion criteria to rule out pre-existing chorioamnionitis

Probably yes;

 

Reason: Confounding factors obtained from patient medical records.

Probably yes;

 

Reason: Study adjusted for confounders.

Probably yes;

 

Reason: Outcomes derived from medical records.

Probably yes;

 

Reason: No missing data.

Probably yes;

 

Reason: No other interventions.

High

 

 

Table of excluded studies

Reference

Reason for exclusion

Al-Dughaishi T, Al-Jabri MMH, Al-Haddabi AH, Gowri V. Trends of Patients' Preferences in the Management of First and Early Second Trimester Pregnancy Loss Towards the Choice of Medical or Surgical Termination of Pregnancy in a Tertiary Care Center in Oman. J Reprod Infertil. 2019 Jan-Mar;20(1):52-56. PMID: 30859082; PMCID: PMC6386795.

No subgroup for second trimester

Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, Atrash HK. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004 Apr;103(4):729-37. doi: 10.1097/01.AOG.0000116260.81570.60. PMID: 15051566.

Not possible to compare medical and instrumental abortion

Bryant AG, Grimes DA, Garrett JM, Stuart GS. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol. 2011 Apr;117(4):788-792. doi: 10.1097/AOG.0b013e31820c3d26. PMID: 21422848.

No suitable outcomes; no subgroup for abortion

Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters. 2008 May;16(31 Suppl):173-82. doi: 10.1016/S0968-8080(08)31379-2. PMID: 18772098.

More recent systematic review available

Kelly T, Suddes J, Howel D, Hewison J, Robson S. Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial. BJOG. 2010 Nov;117(12):1512-20. doi: 10.1111/j.1471-0528.2010.02712.x. Epub 2010 Sep 22. PMID: 20860598.

Included in SR of Schmidt-Hansen 2020

Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update. 2007 Jan-Feb;13(1):37-52. doi: 10.1093/humupd/dml049. Epub 2006 Oct 17. PMID: 17050523.

No systematic review of comparison instrumental and medical abortion

Lohr PA, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester induced abortion. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006714. doi: 10.1002/14651858.CD006714.pub2. PMID: 18254113.

More recent systematic review available

Yilmaz N, Kanat-Pektas M, Kilic S, Gulerman C. Medical or surgical abortion and psychiatric outcomes. J Matern Fetal Neonatal Med. 2010 Jun;23(6):541-4. doi: 10.3109/14767050903191301. PMID: 19701863.

Wrong population: no second trimester (instrumental abortions on patients of up to 12 weeks of gestation)

Beoordelingsdatum en geldigheid

Publicatiedatum  : 20-11-2026

Beoordeeld op geldigheid  : 20-11-2026

Initiatief en autorisatie

Initiatief:
  • Nederlandse Vereniging voor Obstetrie en Gynaecologie
Geautoriseerd door:
  • Ava helpt
  • Koninklijke Nederlandse Organisatie van Verloskundigen
  • Nederlands Genootschap van Abortusartsen
  • Nederlandse Vereniging voor Obstetrie en Gynaecologie

Algemene gegevens

De ontwikkeling/herziening van deze richtlijnmodule werd ondersteund door het Kennisinstituut van de Federatie Medisch Specialisten (www.demedischspecialist.nl/kennisinstituut) en werd gefinancierd uit de Kwaliteitsgelden Medisch Specialisten (SKMS)]. De financier heeft geen enkele invloed gehad op de inhoud van de richtlijnmodule.

Samenstelling werkgroep

Voor het ontwikkelen van de richtlijnmodule is in 2022 een multidisciplinaire werkgroep ingesteld, bestaande uit vertegenwoordigers van alle relevante specialismen (zie hiervoor de Samenstelling van de werkgroep) die betrokken zijn bij de zorg voor cliënten die een tweede trimester zwangerschapsafbreking ondergaan.

 

Werkgroep

  • Dr. I.H. (Ingeborg) Linskens, gynaecoloog-perinatoloog, NVOG (voorzitter)
  • Dr. M.T.M. (Maureen) Franssen, gynaecoloog-perinatoloog, NVOG
  • Dr. M. (Marike) Lemmers, gynaecoloog, NVOG
  • Drs. M.M. (Marco) Brummer, abortusarts, NGvA
  • Drs. R.A.B. (Rodante) van der Waal, verloskundige, KNOV
  • Dr. G. (Gunilla) Kleiverda, gynaecoloog en patiëntenvertegenwoordiger Stichting Ava

 Klankbordgroep

  • Dr. M.C. (Merel) van Maarle, klinisch geneticus, VKGN
  • K. (Karen) Thomson, het Buikencollectief
  • E.M. (Esmée) Sauter, voorheen werkzaam bij Patiëntenfederatie Nederland (tot november 2023)
  • Drs. G. (Gert) van Dijk, beleidsadviseur ethiek, KNMG
  • Dr. mr. A. (Antina) de Jong, adviseur gezondheidsrecht en medische ethiek, KNMG

Met ondersteuning van

  • Dr. F. (Floor) Willeboordse, senior adviseur, Kennisinstituut van de Federatie Medisch Specialisten
  • Drs. D.A.M. (Danique) Middelhuis, junior adviseur, Kennisinstituut van de Federatie Medisch Specialisten
  • Mw. A. (Alies) Oost, medisch informatiespecialist, Kennisinstituut van de Federatie Medisch Specialisten

Belangenverklaringen

De Code ter voorkoming van oneigenlijke beïnvloeding door belangenverstrengeling is gevolgd. Alle werkgroepleden hebben schriftelijk verklaard of zij in de laatste drie jaar directe financiële belangen (betrekking bij een commercieel bedrijf, persoonlijke financiële belangen, onderzoeksfinanciering) of indirecte belangen (persoonlijke relaties, reputatiemanagement) hebben gehad. Gedurende de ontwikkeling of herziening van een module worden wijzigingen in belangen aan de voorzitter doorgegeven. De belangenverklaring wordt opnieuw bevestigd tijdens de commentaarfase.

Een overzicht van de belangen van werkgroepleden en het oordeel over het omgaan met eventuele belangen vindt u in onderstaande tabel. De ondertekende belangenverklaringen zijn op te vragen bij het secretariaat van het Kennisinstituut van de Federatie Medisch Specialisten.

 

Werkgroep

Achternaam werkgroeplid

Functie

Nevenfuncties

Gemelde belangen

Ondernomen actie

Linskens (voorzitter)

Gynaecoloog-perinatoloog Amsterdam UMC

Geen

Geen

Geen restricties

Franssen

Gynaecoloog-perinatoloog

UMCG

Geen

Geen

Geen restricties

Lemmers

Gynaecoloog Jonkerbosch Medisch Specialisten, Canisius Wilhelmina Ziekenhuis Nijmegen.

Richtlijn Hyperemesis gravidarum (waarvoor vacatiegelden)

 

Werkgroep nascholing en implementatie abortuszorg door huisartsen (waarvoor vergoeding vanuit VWS)

 

Herziening module behandeling MTX voor EUG (NVOG)

 

Herziening richtlijn 1e trimester zwangerschapsafbreking (NGvA)

 

Bestuurslid werkgroep gynaecologische endoscopie (WGE)

onbetaald

Geen

Geen restricties

Brummer

Abortusarts bij Mildred Clinics, Stimezo Zwolle en SA Amsterdam met een totaal van meer dan 32 uur per week

Lid Visitatiecommissie bij Nederlandse Genootschap van Abortusartsen, waarvoor vacatiegeld

 

Lid Werkgroep Statutenwijziging bij Nederlands Genootschap van Abortusartsen, waarvoor vacatiegeld

Geen

Geen restricties

Van der Waal

Promovenda (universiteit voor humanistiek, Utrecht)

Verloskundige, waarneming 1e lijn

Eigen promotie-onderzoek is deels gefinancierd door ZonMW, maar valt niet onder onderzoek waar zij aan deelneemt.

Ze schrijft zelf over abortus in het licht van haar eigen onderzoek naar geweld in de reproductieve zorg.

Geen restricties

Kleiverda

Waarnemend gynaecoloog

Onbezoldigd voorzitter Women on Waves

 

Onbezoldigd projectleider onderzoek LUMC mifepriston 50 mg als wekelijkse anticonceptie

Children's Investment Fund Foundation

, Women on Waves, Karolinska Instituut. Mifepriston als wekelijkse anticonceptie. WOMEN&More studie, projectleider

Geen restricties

Klankbordgroep

Achternaam klankbordgroeplid

Functie

Nevenfuncties

Gemelde belangen

Ondernomen actie

Van Maarle

Klinisch Geneticus

AmsterdamUMC

Geen

Geen

Geen restricties

Thomson-Knipschild

Vanaf 1 maart 2024 coordinator bij Het Buikencollectief 

Geen

Geen

Geen restricties

Sauter (tot november 2023)

Voorheen: Adviseur Patiëntenfederatie Nederland

Geen

Geen

Geen restricties

Van Dijk

KNMG, beleidsmedewerker ethiek

Geen

Geen

Geen restricties

De Jong

Adviseur gezondheidsrecht en medische ethiek bij artsenfederatie KNMG.

Advisering KNMG en individuele artsen, betaald.

Geen

Geen restricties

 

Inbreng patiëntenperspectief

Er werd aandacht besteed aan het patiëntenperspectief door afvaardiging van Stichting Ava in de werkgroep. De verkregen input is meegenomen bij het opstellen van de uitgangsvragen, de keuze voor de uitkomstmaten en bij het opstellen van de overwegingen (zie per module ook “Waarden en voorkeuren van patiënten”). De conceptrichtlijn is tevens voor commentaar voorgelegd aan Stichting Ava, Het Buikencollectief en Patiëntenfederatie Nederland en de eventueel aangeleverde commentaren zijn beoordeeld en verwerkt.

 

Kwalitatieve raming van mogelijke financiële gevolgen in het kader van de Wkkgz

Bij de richtlijnmodule is conform de Wet kwaliteit, klachten en geschillen zorg (Wkkgz) een kwalitatieve raming uitgevoerd om te beoordelen of de aanbevelingen mogelijk leiden tot substantiële financiële gevolgen. Bij het uitvoeren van deze beoordeling is de richtlijnmodule op verschillende domeinen getoetst (zie het stroomschema op de Richtlijnendatabase).

 

Module

Uitkomst raming

Toelichting

Methode zwangerschapsafbreking in het tweede trimester

Geen financiële gevolgen

Uit de toetsing volgt dat de aanbeveling(en) niet breed toepasbaar zijn (<5000 patiënten) en zal daarom naar verwachting geen substantiële gevolgen hebben voor de collectieve uitgaven.

 

Werkwijze

AGREE

Deze richtlijnmodule is opgesteld conform de eisen vermeld in het rapport Medisch Specialistische Richtlijnen 3.0 van de adviescommissie Richtlijnen van de Raad Kwaliteit. Dit rapport is gebaseerd op het AGREE II instrument (Appraisal of Guidelines for Research & Evaluation II; Brouwers, 2010).

 

Knelpuntenanalyse en uitgangsvragen

Tijdens de voorbereidende fase inventariseerde de werkgroep de knelpunten in de zorg voor cliënten met een tweede trimester zwangerschapsafbreking. Tevens zijn er knelpunten aangedragen door Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG), Nederlands Genootschap van Abortusartsen (NGvA), Koninklijke Nederlandse Organisatie van Verloskundigen (KNOV), Patiëntenfederatie Nederland (PFN), Inspectie voor de Gezondheidszorg en Jeugd (IGJ), Beroepsvereniging van Professionals in Sociaal Werk (BPSW), Nederlandse Vereniging van Ziekenhuizen (NVZ), Verpleegkundigen & Verzorgenden Nederland (V&VN), Zorginstituut Nederland (ZiNL), Zelfstandige Klinieken Nederland (ZKN), Zorgverzekeraars Nederland (ZN), Vereniging Innovatieve Geneesmiddelen (VIG) en Koninklijke Nederlanse Maatschappij tot bevordering der Geneeskunst (KNMG) via een schriftelijke knelpunteninventarisatie.

 

Op basis van de uitkomsten van de knelpuntenanalyse zijn door de werkgroep concept-uitgangsvragen opgesteld en definitief vastgesteld.

 

Uitkomstmaten

Na het opstellen van de zoekvraag behorende bij de uitgangsvraag inventariseerde de werkgroep welke uitkomstmaten voor de patiënt relevant zijn, waarbij zowel naar gewenste als ongewenste effecten werd gekeken. Hierbij werd een maximum van acht uitkomstmaten gehanteerd. De werkgroep waardeerde deze uitkomstmaten volgens hun relatieve belang bij de besluitvorming rondom aanbevelingen, als cruciaal (kritiek voor de besluitvorming), belangrijk (maar niet cruciaal) en onbelangrijk. Tevens definieerde de werkgroep tenminste voor de cruciale uitkomstmaten welke verschillen zij klinisch (patiënt) relevant vonden.

 

Methode literatuursamenvatting

Een uitgebreide beschrijving van de strategie voor zoeken en selecteren van literatuur is te vinden onder ‘Zoeken en selecteren’ onder Onderbouwing. Indien mogelijk werd de data uit verschillende studies gepoold in een random-effects model. Review Manager 5.4 werd gebruikt voor de statistische analyses. De beoordeling van de kracht van het wetenschappelijke bewijs wordt hieronder toegelicht.

 

Beoordelen van de kracht van het wetenschappelijke bewijs

De kracht van het wetenschappelijke bewijs werd bepaald volgens de GRADE-methode. GRADE staat voor ‘Grading Recommendations Assessment, Development and Evaluation’ (zie http://www.gradeworkinggroup.org/). De basisprincipes van de GRADE-methodiek zijn: het benoemen en prioriteren van de klinisch (patiënt) relevante uitkomstmaten, een systematische review per uitkomstmaat, en een beoordeling van de bewijskracht per uitkomstmaat op basis van de acht GRADE-domeinen (domeinen voor downgraden: risk of bias, inconsistentie, indirectheid, imprecisie, en publicatiebias; domeinen voor upgraden: dosis-effect relatie, groot effect, en residuele plausibele confounding).

GRADE onderscheidt vier gradaties voor de kwaliteit van het wetenschappelijk bewijs: hoog, redelijk, laag en zeer laag. Deze gradaties verwijzen naar de mate van zekerheid die er bestaat over de literatuurconclusie, in het bijzonder de mate van zekerheid dat de literatuurconclusie de aanbeveling adequaat ondersteunt (Schünemann, 2013; Hultcrantz, 2017).

 

GRADE

Definitie

Hoog

  • er is hoge zekerheid dat het ware effect van behandeling dichtbij het geschatte effect van behandeling ligt;
  • het is zeer onwaarschijnlijk dat de literatuurconclusie klinisch relevant verandert wanneer er resultaten van nieuw grootschalig onderzoek aan de literatuuranalyse worden toegevoegd.

Redelijk

  • er is redelijke zekerheid dat het ware effect van behandeling dichtbij het geschatte effect van behandeling ligt;
  • het is mogelijk dat de conclusie klinisch relevant verandert wanneer er resultaten van nieuw grootschalig onderzoek aan de literatuuranalyse worden toegevoegd.

Laag

  • er is lage zekerheid dat het ware effect van behandeling dichtbij het geschatte effect van behandeling ligt;
  • er is een reële kans dat de conclusie klinisch relevant verandert wanneer er resultaten van nieuw grootschalig onderzoek aan de literatuuranalyse worden toegevoegd.

Zeer laag

  • er is zeer lage zekerheid dat het ware effect van behandeling dichtbij het geschatte effect van behandeling ligt;
  • de literatuurconclusie is zeer onzeker.

 

Bij het beoordelen (graderen) van de kracht van het wetenschappelijk bewijs in richtlijnen volgens de GRADE-methodiek spelen grenzen voor klinische besluitvorming een belangrijke rol (Hultcrantz, 2017). Dit zijn de grenzen die bij overschrijding aanleiding zouden geven tot een aanpassing van de aanbeveling. Om de grenzen voor klinische besluitvorming te bepalen moeten alle relevante uitkomstmaten en overwegingen worden meegewogen. De grenzen voor klinische besluitvorming zijn daarmee niet één op één vergelijkbaar met het minimaal klinisch relevant verschil (Minimal Clinically Important Difference, MCID). Met name in situaties waarin een interventie geen belangrijke nadelen heeft en de kosten relatief laag zijn, kan de grens voor klinische besluitvorming met betrekking tot de effectiviteit van de interventie bij een lagere waarde (dichter bij het nuleffect) liggen dan de MCID (Hultcrantz, 2017).

 

Overwegingen (van bewijs naar aanbeveling)

Om te komen tot een aanbeveling zijn naast (de kwaliteit van) het wetenschappelijke bewijs ook andere aspecten belangrijk en worden meegewogen, zoals aanvullende argumenten uit bijvoorbeeld de biomechanica of fysiologie, waarden en voorkeuren van patiënten, kosten (middelenbeslag), aanvaardbaarheid, haalbaarheid en implementatie. Deze aspecten zijn systematisch vermeld en beoordeeld (gewogen) onder het kopje ‘Overwegingen’ en kunnen (mede) gebaseerd zijn op expert opinion. Hierbij is gebruik gemaakt van een gestructureerd format gebaseerd op het evidence-to-decision framework van de internationale GRADE Working Group (Alonso-Coello, 2016a; Alonso-Coello 2016b). Dit evidence-to-decision framework is een integraal onderdeel van de GRADE methodiek.

 

Formuleren van aanbevelingen

De aanbevelingen geven antwoord op de uitgangsvraag en zijn gebaseerd op het beschikbare wetenschappelijke bewijs en de belangrijkste overwegingen, en een weging van de gunstige en ongunstige effecten van de relevante interventies. De kracht van het wetenschappelijk bewijs en het gewicht dat door de werkgroep wordt toegekend aan de overwegingen, bepalen samen de sterkte van de aanbeveling. Conform de GRADE-methodiek sluit een lage bewijskracht van conclusies in de systematische literatuuranalyse een sterke aanbeveling niet a priori uit, en zijn bij een hoge bewijskracht ook zwakke aanbevelingen mogelijk (Agoritsas, 2017; Neumann, 2016). De sterkte van de aanbeveling wordt altijd bepaald door weging van alle relevante argumenten tezamen. De werkgroep heeft bij elke aanbeveling opgenomen hoe zij tot de richting en sterkte van de aanbeveling zijn gekomen.

 

In de GRADE-methodiek wordt onderscheid gemaakt tussen sterke en zwakke (of conditionele) aanbevelingen. De sterkte van een aanbeveling verwijst naar de mate van zekerheid dat de voordelen van de interventie opwegen tegen de nadelen (of vice versa), gezien over het hele spectrum van patiënten waarvoor de aanbeveling is bedoeld. De sterkte van een aanbeveling heeft duidelijke implicaties voor patiënten, behandelaars en beleidsmakers (zie onderstaande tabel). Een aanbeveling is geen dictaat, zelfs een sterke aanbeveling gebaseerd op bewijs van hoge kwaliteit (GRADE gradering HOOG) zal niet altijd van toepassing zijn, onder alle mogelijke omstandigheden en voor elke individuele patiënt.

 

Implicaties van sterke en zwakke aanbevelingen voor verschillende richtlijngebruikers

 

 

Sterke aanbeveling

Zwakke (conditionele) aanbeveling

Voor patiënten

De meeste patiënten zouden de aanbevolen interventie of aanpak kiezen en slechts een klein aantal niet.

Een aanzienlijk deel van de patiënten zouden de aanbevolen interventie of aanpak kiezen, maar veel patiënten ook niet. 

Voor behandelaars

De meeste patiënten zouden de aanbevolen interventie of aanpak moeten ontvangen.

Er zijn meerdere geschikte interventies of aanpakken. De patiënt moet worden ondersteund bij de keuze voor de interventie of aanpak die het beste aansluit bij zijn of haar waarden en voorkeuren.

Voor beleidsmakers

De aanbevolen interventie of aanpak kan worden gezien als standaardbeleid.

Beleidsbepaling vereist uitvoerige discussie met betrokkenheid van veel stakeholders. Er is een grotere kans op lokale beleidsverschillen. 

 

Organisatie van zorg

In de knelpuntenanalyse en bij de ontwikkeling van de richtlijnmodule is expliciet aandacht geweest voor de organisatie van zorg: alle aspecten die randvoorwaardelijk zijn voor het verlenen van zorg (zoals coördinatie, communicatie, (financiële) middelen, mankracht en infrastructuur). Randvoorwaarden die relevant zijn voor het beantwoorden van deze specifieke uitgangsvraag zijn genoemd bij de overwegingen. Meer algemene, overkoepelende, of bijkomende aspecten van de organisatie van zorg worden behandeld in de module over randvoorwaarden.

 

Commentaar- en autorisatiefase

De conceptrichtlijnmodule werd aan de betrokken (wetenschappelijke) verenigingen en (patiënt) organisaties voorgelegd ter commentaar. De commentaren werden verzameld en besproken met de werkgroep. Naar aanleiding van de commentaren werd de conceptrichtlijnmodule aangepast en definitief vastgesteld door de werkgroep. De definitieve richtlijnmodule werd aan de deelnemende (wetenschappelijke) verenigingen en (patiënt) organisaties voorgelegd voor autorisatie en door hen geautoriseerd dan wel geaccordeerd.

 

Literatuur

Agoritsas T, Merglen A, Heen AF, Kristiansen A, Neumann I, Brito JP, Brignardello-Petersen R, Alexander PE, Rind DM, Vandvik PO, Guyatt GH. UpToDate adherence to GRADE criteria for strong recommendations: an analytical survey. BMJ Open. 2017 Nov 16;7(11):e018593. doi: 10.1136/bmjopen-2017-018593. PubMed PMID: 29150475; PubMed Central PMCID: PMC5701989.

 

Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016 Jun 28;353:i2016. doi: 10.1136/bmj.i2016. PubMed PMID: 27353417.

 

Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, Schünemann HJ; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016 Jun 30;353:i2089. doi: 10.1136/bmj.i2089. PubMed PMID: 27365494.

 

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010 Dec 14;182(18):E839-42. doi: 10.1503/cmaj.090449. Epub 2010 Jul 5. Review. PubMed PMID: 20603348; PubMed Central PMCID: PMC3001530.

 

Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, Katikireddi SV, Östlund P, Tranæus S, Christensen R, Gartlehner G, Brozek J, Izcovich A, Schünemann H, Guyatt G. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017 Jul;87:4-13. doi: 10.1016/j.jclinepi.2017.05.006. Epub 2017 May 18. PubMed PMID: 28529184; PubMed Central PMCID: PMC6542664.

 

Medisch Specialistische Richtlijnen 2.0 (2012). Adviescommissie Richtlijnen van de Raad Kwalitieit. http://richtlijnendatabase.nl/over_deze_site/over_richtlijnontwikkeling.html

 

Neumann I, Santesso N, Akl EA, Rind DM, Vandvik PO, Alonso-Coello P, Agoritsas T, Mustafa RA, Alexander PE, Schünemann H, Guyatt GH. A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. J Clin Epidemiol. 2016 Apr;72:45-55. doi: 10.1016/j.jclinepi.2015.11.017. Epub 2016 Jan 6. Review. PubMed PMID: 26772609.

 

Schünemann H, Brożek J, Guyatt G, et al. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html.

Zoekverantwoording

Embase.com

No.

Query

Results

#10

#3 AND (#6 OR #7) NOT (#8 OR #9) = observationeel

745

#9

#3 AND #5 NOT #8 = RCT

419

#8

#3 AND #4 = SR

103

#7

'case control study'/de OR 'comparative study'/exp OR 'control group'/de OR 'controlled study'/de OR 'controlled clinical trial'/de OR 'crossover procedure'/de OR 'double blind procedure'/de OR 'phase 2 clinical trial'/de OR 'phase 3 clinical trial'/de OR 'phase 4 clinical trial'/de OR 'pretest posttest design'/de OR 'pretest posttest control group design'/de OR 'quasi experimental study'/de OR 'single blind procedure'/de OR 'triple blind procedure'/de OR (((control OR controlled) NEAR/6 trial):ti,ab,kw) OR (((control OR controlled) NEAR/6 (study OR studies)):ti,ab,kw) OR (((control OR controlled) NEAR/1 active):ti,ab,kw) OR 'open label*':ti,ab,kw OR (((double OR two OR three OR multi OR trial) NEAR/1 (arm OR arms)):ti,ab,kw) OR ((allocat* NEAR/10 (arm OR arms)):ti,ab,kw) OR placebo*:ti,ab,kw OR 'sham-control*':ti,ab,kw OR (((single OR double OR triple OR assessor) NEAR/1 (blind* OR masked)):ti,ab,kw) OR nonrandom*:ti,ab,kw OR 'non-random*':ti,ab,kw OR 'quasi-experiment*':ti,ab,kw OR crossover:ti,ab,kw OR 'cross over':ti,ab,kw OR 'parallel group*':ti,ab,kw OR 'factorial trial':ti,ab,kw OR ((phase NEAR/5 (study OR trial)):ti,ab,kw) OR ((case* NEAR/6 (matched OR control*)):ti,ab,kw) OR ((match* NEAR/6 (pair OR pairs OR cohort* OR control* OR group* OR healthy OR age OR sex OR gender OR patient* OR subject* OR participant*)):ti,ab,kw) OR ((propensity NEAR/6 (scor* OR match*)):ti,ab,kw) OR versus:ti OR vs:ti OR compar*:ti OR ((compar* NEAR/1 study):ti,ab,kw) OR (('major clinical study'/de OR 'clinical study'/de OR 'cohort analysis'/de OR 'observational study'/de OR 'cross-sectional study'/de OR 'multicenter study'/de OR 'correlational study'/de OR 'follow up'/de OR cohort*:ti,ab,kw OR 'follow up':ti,ab,kw OR followup:ti,ab,kw OR longitudinal*:ti,ab,kw OR prospective*:ti,ab,kw OR retrospective*:ti,ab,kw OR observational*:ti,ab,kw OR 'cross sectional*':ti,ab,kw OR cross?ectional*:ti,ab,kw OR multicent*:ti,ab,kw OR 'multi-cent*':ti,ab,kw OR consecutive*:ti,ab,kw) AND (group:ti,ab,kw OR groups:ti,ab,kw OR subgroup*:ti,ab,kw OR versus:ti,ab,kw OR vs:ti,ab,kw OR compar*:ti,ab,kw OR 'odds ratio*':ab OR 'relative odds':ab OR 'risk ratio*':ab OR 'relative risk*':ab OR 'rate ratio':ab OR aor:ab OR arr:ab OR rrr:ab OR ((('or' OR 'rr') NEAR/6 ci):ab)))

13855850

#6

'major clinical study'/de OR 'clinical study'/de OR 'case control study'/de OR 'family study'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 'comparative study'/de OR 'cohort analysis'/de OR ((cohort NEAR/1 (study OR studies)):ab,ti) OR (('case control' NEAR/1 (study OR studies)):ab,ti) OR (('follow up' NEAR/1 (study OR studies)):ab,ti) OR (observational NEAR/1 (study OR studies)) OR ((epidemiologic NEAR/1 (study OR studies)):ab,ti) OR (('cross sectional' NEAR/1 (study OR studies)):ab,ti)

7500270

#5

'clinical trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp OR 'prospective study'/exp OR rct:ab,ti OR random*:ab,ti OR 'single blind':ab,ti OR 'randomised controlled trial':ab,ti OR 'randomized controlled trial'/exp OR placebo*:ab,ti

3728780

#4

'meta analysis'/exp OR 'meta analysis (topic)'/exp OR metaanaly*:ti,ab OR 'meta analy*':ti,ab OR metanaly*:ti,ab OR 'systematic review'/de OR 'cochrane database of systematic reviews'/jt OR prisma:ti,ab OR prospero:ti,ab OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab) OR ((systemic* NEAR/1 review*):ti,ab) OR (((systemati* OR literature OR database* OR 'data base*') NEAR/10 search*):ti,ab) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab) OR (((literature NEAR/3 review*):ti,ab) AND (search*:ti,ab OR database*:ti,ab OR 'data base*':ti,ab)) OR (('data extraction':ti,ab OR 'data source*':ti,ab) AND 'study selection':ti,ab) OR ('search strategy':ti,ab AND 'selection criteria':ti,ab) OR ('data source*':ti,ab AND 'data synthesis':ti,ab) OR medline:ab OR pubmed:ab OR embase:ab OR cochrane:ab OR (((critical OR rapid) NEAR/2 (review* OR overview* OR synthes*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synthes*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynthes*:ti,ab OR 'meta synthes*':ti,ab

902105

#3

#2 AND [2000-2023]/py

2038

#2

#1 NOT ('conference abstract'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it) NOT (('animal'/exp OR 'animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp)

3764

#1

'second trimester abortion'/exp OR (((((second OR 2nd OR mid) NEAR/3 trimester):ti,ab,kw) OR secondtrimester:ti,ab,kw OR midtrimester:ti,ab,kw OR 'second trimester pregnancy'/exp) AND ('induced abortion'/exp OR 'abortive agent'/exp OR 'abortifacient*':ti,ab,kw OR 'abortivum':ti,ab,kw OR ((dilat* NEAR/3 (evacuation OR curettage)):ti,ab,kw) OR ((vacuum NEAR/3 (curettage OR aspiration)):ti,ab,kw) OR (((abortion* OR abortive OR terminat*) NEAR/3 (induce* OR provoke* OR provocat* OR techni* OR eugenic OR therapeutic* OR surgical* OR mechanical* OR medication OR drug* OR agent* OR artificial OR vacuum* OR medical* OR curettage OR dilatation OR dilation)):ti,ab,kw) OR 'corlux':ti,ab,kw OR 'corluxin':ti,ab,kw OR 'korlym':ti,ab,kw OR 'lunarette':ti,ab,kw OR 'mifegest':ti,ab,kw OR 'mifegyne':ti,ab,kw OR 'mifeprex':ti,ab,kw OR 'mifepristone':ti,ab,kw OR 'miffee':ti,ab,kw OR 'pictovir':ti,ab,kw OR 'angusta':ti,ab,kw OR 'cityl':ti,ab,kw OR 'cyprostol':ti,ab,kw OR 'cytolog':ti,ab,kw OR 'cytotec':ti,ab,kw OR 'gastotec':ti,ab,kw OR 'gastrul':ti,ab,kw OR 'gymiso':ti,ab,kw OR 'hemoprostol':ti,ab,kw OR 'isprelor':ti,ab,kw OR 'misel':ti,ab,kw OR 'misodel':ti,ab,kw OR 'misofar':ti,ab,kw OR 'misoone':ti,ab,kw OR 'misopress':ti,ab,kw OR 'misoprostil':ti,ab,kw OR 'misoprostol':ti,ab,kw OR 'misotrol':ti,ab,kw OR 'mispregnol':ti,ab,kw OR 'mysodelle':ti,ab,kw OR 'topogyne':ti,ab,kw OR 'nalador':ti,ab,kw OR 'sulproston*':ti,ab,kw OR 'cervidil':ti,ab,kw OR 'cerviprime':ti,ab,kw OR 'cerviprost':ti,ab,kw OR 'dinoprostin':ti,ab,kw OR 'dinoprostone':ti,ab,kw OR 'minprostin':ti,ab,kw OR 'prandin':ti,ab,kw OR 'prepidil':ti,ab,kw OR 'primiprost':ti,ab,kw OR 'propess':ti,ab,kw OR 'prostarmon':ti,ab,kw OR 'prostenon':ti,ab,kw OR 'prostin*':ti,ab,kw OR 'prostaglandin'/exp OR 'prostaglandin*':ti,ab,kw OR prostanoid*:ti,ab,kw))

4571

 

Ovid/Medline

#

Searches

Results

10

(3 and (6 or 7)) not (8 or 9) = observationeel

590

9

(3 and 5) not 8 = RCT

262

8

3 and 4 = SR

78

7

Case-control Studies/ or clinical trial, phase ii/ or clinical trial, phase iii/ or clinical trial, phase iv/ or comparative study/ or control groups/ or controlled before-after studies/ or controlled clinical trial/ or double-blind method/ or historically controlled study/ or matched-pair analysis/ or single-blind method/ or (((control or controlled) adj6 (study or studies or trial)) or (compar* adj (study or studies)) or ((control or controlled) adj1 active) or "open label*" or ((double or two or three or multi or trial) adj (arm or arms)) or (allocat* adj10 (arm or arms)) or placebo* or "sham-control*" or ((single or double or triple or assessor) adj1 (blind* or masked)) or nonrandom* or "non-random*" or "quasi-experiment*" or "parallel group*" or "factorial trial" or "pretest posttest" or (phase adj5 (study or trial)) or (case* adj6 (matched or control*)) or (match* adj6 (pair or pairs or cohort* or control* or group* or healthy or age or sex or gender or patient* or subject* or participant*)) or (propensity adj6 (scor* or match*))).ti,ab,kf. or (confounding adj6 adjust*).ti,ab. or (versus or vs or compar*).ti. or ((exp cohort studies/ or epidemiologic studies/ or multicenter study/ or observational study/ or seroepidemiologic studies/ or (cohort* or 'follow up' or followup or longitudinal* or prospective* or retrospective* or observational* or multicent* or 'multi-cent*' or consecutive*).ti,ab,kf.) and ((group or groups or subgroup* or versus or vs or compar*).ti,ab,kf. or ('odds ratio*' or 'relative odds' or 'risk ratio*' or 'relative risk*' or aor or arr or rrr).ab. or (("OR" or "RR") adj6 CI).ab.)) or practice guideline.pt.

5386137

6

Epidemiologic studies/ or case control studies/ or exp cohort studies/ or Controlled Before-After Studies/ or Case control.tw. or cohort.tw. or Cohort analy$.tw. or (Follow up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw. or Retrospective*.tw. or prospective*.tw. or consecutive*.tw. or Cross sectional.tw. or Cross-sectional studies/ or historically controlled study/ or interrupted time series analysis/ [Onder exp cohort studies vallen ook longitudinale, prospectieve en retrospectieve studies]

4366808

5

exp clinical trial/ or randomized controlled trial/ or exp clinical trials as topic/ or randomized controlled trials as topic/ or Random Allocation/ or Double-Blind Method/ or Single-Blind Method/ or (clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or randomized controlled trial or multicenter study or clinical trial).pt. or random*.ti,ab. or (clinic* adj trial*).tw. or ((singl* or doubl* or treb* or tripl*) adj (blind$3 or mask$3)).tw. or Placebos/ or placebo*.tw.

2554603

4

meta-analysis/ or meta-analysis as topic/ or (metaanaly* or meta-analy* or metanaly*).ti,ab,kf. or systematic review/ or cochrane.jw. or (prisma or prospero).ti,ab,kf. or ((systemati* or scoping or umbrella or "structured literature") adj3 (review* or overview*)).ti,ab,kf. or (systemic* adj1 review*).ti,ab,kf. or ((systemati* or literature or database* or data-base*) adj10 search*).ti,ab,kf. or ((structured or comprehensive* or systemic*) adj3 search*).ti,ab,kf. or ((literature adj3 review*) and (search* or database* or data-base*)).ti,ab,kf. or (("data extraction" or "data source*") and "study selection").ti,ab,kf. or ("search strategy" and "selection criteria").ti,ab,kf. or ("data source*" and "data synthesis").ti,ab,kf. or (medline or pubmed or embase or cochrane).ab. or ((critical or rapid) adj2 (review* or overview* or synthes*)).ti. or (((critical* or rapid*) adj3 (review* or overview* or synthes*)) and (search* or database* or data-base*)).ab. or (metasynthes* or meta-synthes*).ti,ab,kf.

649397

3

limit 2 to yr="2000 -Current"

1822

2

1 not (comment/ or editorial/ or letter/) not ((exp animals/ or exp models, animal/) not humans/)

3990

1

((((second or 2nd or mid) adj3 trimester) or secondtrimester or midtrimester).ti,ab,kf. or Pregnancy Trimester, Second/) and (exp Abortion, Induced/ or exp Abortifacient Agents/ or 'abortifacient*'.ti,ab,kf. or 'abortivum'.ti,ab,kf. or (dilat* adj3 (evacuation or curettage)).ti,ab,kf. or (vacuum adj3 (curettage or aspiration)).ti,ab,kf. or ((abortion* or abortive or terminat*) adj3 (induce* or provoke* or provocat* or techni* or eugenic or therapeutic* or surgical* or mechanical* or medication or drug* or agent* or artificial or vacuum* or medical* or curettage or dilatation or dilation)).ti,ab,kf. or 'corlux'.ti,ab,kf. or 'corluxin'.ti,ab,kf. or 'korlym'.ti,ab,kf. or 'lunarette'.ti,ab,kf. or 'mifegest'.ti,ab,kf. or 'mifegyne'.ti,ab,kf. or 'mifeprex'.ti,ab,kf. or 'mifepristone'.ti,ab,kf. or 'miffee'.ti,ab,kf. or 'pictovir'.ti,ab,kf. or 'angusta'.ti,ab,kf. or 'cityl'.ti,ab,kf. or 'cyprostol'.ti,ab,kf. or 'cytolog'.ti,ab,kf. or 'cytotec'.ti,ab,kf. or 'gastotec'.ti,ab,kf. or 'gastrul'.ti,ab,kf. or 'gymiso'.ti,ab,kf. or 'hemoprostol'.ti,ab,kf. or 'isprelor'.ti,ab,kf. or 'misel'.ti,ab,kf. or 'misodel'.ti,ab,kf. or 'misofar'.ti,ab,kf. or 'misoone'.ti,ab,kf. or 'misopress'.ti,ab,kf. or 'misoprostil'.ti,ab,kf. or 'misoprostol'.ti,ab,kf. or 'misotrol'.ti,ab,kf. or 'mispregnol'.ti,ab,kf. or 'mysodelle'.ti,ab,kf. or 'topogyne'.ti,ab,kf. or 'nalador'.ti,ab,kf. or 'sulproston*'.ti,ab,kf. or 'cervidil'.ti,ab,kf. or 'cerviprime'.ti,ab,kf. or 'cerviprost'.ti,ab,kf. or 'dinoprostin'.ti,ab,kf. or 'dinoprostone'.ti,ab,kf. or 'minprostin'.ti,ab,kf. or 'prandin'.ti,ab,kf. or 'prepidil'.ti,ab,kf. or 'primiprost'.ti,ab,kf. or 'propess'.ti,ab,kf. or 'prostarmon'.ti,ab,kf. or 'prostenon'.ti,ab,kf. or 'prostin*'.ti,ab,kf. or exp Prostaglandins/ or 'prostaglandin*'.ti,ab,kf. or prostanoid*.ti,ab,kf.)

4194

Volgende:
Randvoorwaarden rondom zwangerschapsafbreking in het tweede trimester